Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
51.5 /100
Rank 21 out of 131 Industries -
Advance/Decline
174/180
-
No. of Companies354
-
Avg. Market Cap11,869
-
Price to Earning Ratio6.66
-
Price to Earning Growth Ratio0.83
-
Price to Book Ratio26.11
-
Return on Equity49.03
-
Return on Capital Employed-
-
Return on Assets11.22
-
Dividend yield 1 year %0.88 %
-
Net Profit Growth Annual YoY %-10.14 %
-
Net Profit Growth Qtr YoY %-62.01 %
-
Net Profit Growth Qtr QoQ %-70.32 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
413,568.0
|
234
|
L
 0.7%
H
229.2
235.4
|
L
 6.8%
H
216.2
239.3
|
L
 3.1%
H
211.7
239.3
|
L
 13.2%
H
205.1
244.8
|
L
 41.2%
H
163.8
244.8
|
L
 54.1%
H
131.0
244.8
|
L
 137.9%
H
98.6
244.8
|
L
 289.9%
H
50.7
244.8
|
| Adc Therapeutics SA |
|
491.8
|
4.0
|
L
 0.3%
H
3.9
4.2
|
L
 -1.7%
H
3.9
4.4
|
L
 -3.9%
H
3.6
4.8
|
L
 26.8%
H
3.0
4.8
|
L
 66.1%
H
1.1
4.8
|
L
 -7.9%
H
0.4
6.0
|
L
 -88.4%
H
0.4
38.3
|
L
H
0.4
56.6
|
| Amneal Pharmaceuticals Inc |
|
3,640.3
|
11.6
|
L
 -0.5%
H
11.5
11.9
|
L
 1.9%
H
11.4
12.1
|
L
 17.3%
H
9.8
12.1
|
L
 22.5%
H
9.2
12.1
|
L
 36.7%
H
6.7
12.1
|
L
 419.3%
H
1.2
12.1
|
L
 183.8%
H
1.2
12.1
|
L
 -71.5%
H
1.2
45
|
| Annovis Bio Inc |
|
80.3
|
3.0
|
L
 29.5%
H
2.4
4
|
L
 51.5%
H
2.0
4
|
L
 49.3%
H
1.9
4
|
L
 10.6%
H
1.6
4
|
L
 -55.7%
H
1.1
7.5
|
L
 -76.4%
H
1.1
23.9
|
L
 -39.9%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,271.3
|
6.1
|
L
 -2.4%
H
6.0
6.3
|
L
 -7.8%
H
6.0
7.0
|
L
 2%
H
5.9
7.2
|
L
 -26.5%
H
5.9
8.4
|
L
 -27.7%
H
4.3
8.7
|
L
 -12.1%
H
4.0
11.5
|
L
 -69.2%
H
4.0
34.8
|
L
 -91.6%
H
4.0
119.9
|
| Bristol-Myers Squibb |
|
95,293.6
|
46.8
|
L
 0.3%
H
46.5
47.7
|
L
 0.3%
H
46.1
50.0
|
L
 7.9%
H
42.5
50.0
|
L
 -3.4%
H
42.5
50.0
|
L
 -16.7%
H
42.5
63.3
|
L
 -38.5%
H
39.4
81.4
|
L
 -27.4%
H
39.4
81.4
|
L
 -28.0%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
530.5
|
10.1
|
L
 -0.1%
H
10.0
10.4
|
L
 -0.6%
H
9.9
11.0
|
L
 7.5%
H
9.0
13.4
|
L
 14.3%
H
7.5
13.4
|
L
 21.0%
H
4.0
13.4
|
L
 -17.1%
H
1.4
16.7
|
L
 -88.4%
H
1.4
127.2
|
L
 -70.3%
H
1.4
137.6
|
| GSK Plc ADR |
|
95,483.8
|
47.5
|
L
 0.7%
H
47.4
48.0
|
L
 1.9%
H
46.6
48.7
|
L
 8.6%
H
42.8
48.7
|
L
 20.8%
H
38.6
48.7
|
L
 42.5%
H
31.7
48.7
|
L
 44.4%
H
31.7
48.7
|
L
 22.7%
H
28.5
48.7
|
L
 16.1%
H
28.5
49.1
|
| Johnson & Johnson |
|
480,847.1
|
199.6
|
L
 1.9%
H
195.9
200.3
|
L
 7.0%
H
185.1
200.3
|
L
 3.9%
H
184.7
200.3
|
L
 13.0%
H
173.3
200.3
|
L
 29.6%
H
140.7
200.3
|
L
 15.1%
H
140.7
200.3
|
L
 32.3%
H
140.7
200.3
|
L
 97.2%
H
94.3
200.3
|
| Eli Lilly |
|
914,440.7
|
1,021.7
|
L
 -0.4%
H
998.3
1032.1
|
L
 10.5%
H
938.4
1033.6
|
L
 24.7%
H
783.8
1033.6
|
L
 45.7%
H
685.2
1033.6
|
L
 35.9%
H
623.8
1033.6
|
L
 189.5%
H
302.1
1033.6
|
L
 626.7%
H
138.6
1033.6
|
L
 1157.8%
H
64.2
1033.6
|
| Merck & Company |
|
230,480.6
|
92.9
|
L
 -0.1%
H
92.7
94.8
|
L
 7.6%
H
85.8
95.1
|
L
 10.7%
H
82.0
95.1
|
L
 10.3%
H
77.6
95.1
|
L
 -3.6%
H
73.3
105.1
|
L
 -7.1%
H
73.3
134.6
|
L
 21.4%
H
68.4
134.6
|
L
 81.2%
H
45.8
134.6
|
| Novo Nordisk ADR |
|
215,331.0
|
48.5
|
L
 0.4%
H
47.7
49.2
|
L
 6.1%
H
45.6
50.4
|
L
 -13.6%
H
45.2
56.2
|
L
 -6.5%
H
45.2
62.3
|
L
 -52.4%
H
45.1
112.5
|
L
 -14.5%
H
45.1
148.2
|
L
 44.0%
H
32.9
148.2
|
L
 82.0%
H
15.5
148.2
|
| Novartis AG ADR |
|
252,417.1
|
131.6
|
L
 0.2%
H
131.5
133.2
|
L
 4.1%
H
126.3
134
|
L
 0.6%
H
121.6
134
|
L
 5.9%
H
121.6
134
|
L
 27.6%
H
96.1
134
|
L
 57.5%
H
80.0
134
|
L
 52.2%
H
74.1
134
|
L
 70.9%
H
59.2
134
|
| Organon Co |
|
1,988.9
|
7.7
|
L
 1.6%
H
7.4
7.8
|
L
 12.8%
H
6.9
7.9
|
L
 -18.4%
H
6.2
9.4
|
L
 -19.0%
H
6.2
11.3
|
L
 -49.1%
H
6.2
17.2
|
L
 -68.6%
H
6.2
32.4
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare |
|
2,836.0
|
59.0
|
L
 -1.7%
H
58.9
60.1
|
L
 -1.6%
H
58.5
61.9
|
L
 -4.6%
H
58.5
63.6
|
L
 -9.3%
H
58.5
68.6
|
L
 -28.4%
H
58.5
90.0
|
L
 1.1%
H
56.0
90.0
|
L
 62.0%
H
34.3
90.0
|
L
 23.2%
H
26.3
90.0
|
| Pfizer |
|
142,597.5
|
25.1
|
L
 0.1%
H
25.0
25.6
|
L
 2.7%
H
23.9
26.5
|
L
 3.5%
H
23.9
26.5
|
L
 -0.2%
H
23.6
27.7
|
L
 0.2%
H
20.9
27.7
|
L
 -47.8%
H
20.9
54.9
|
L
 -29.1%
H
20.9
61.7
|
L
 -20.2%
H
20.9
61.7
|
| Perrigo Company plc |
|
1,866.2
|
13.6
|
L
 -1.6%
H
13.4
13.8
|
L
 -6.1%
H
13.4
14.5
|
L
 -37.0%
H
13.4
22.0
|
L
 -40.3%
H
13.4
24.6
|
L
 -49.4%
H
13.4
30.9
|
L
 -58.7%
H
13.4
40.3
|
L
 -72.4%
H
13.4
50.9
|
L
 -90.9%
H
13.4
156.0
|
| Dr Reddys Laboratories ADR |
|
11,622.0
|
14.0
|
L
 0.1%
H
13.7
14.0
|
L
 3.7%
H
13.4
14.0
|
L
 -1.8%
H
13.1
15.0
|
L
 -1.8%
H
13.1
15.1
|
L
 -1.5%
H
12.3
16.2
|
L
 26.8%
H
10.2
74.9
|
L
 9.2%
H
9.6
74.9
|
L
 36.1%
H
5.6
74.9
|
| Takeda Pharmaceutical Co ADR |
|
44,670.9
|
14.1
|
L
 -1.1%
H
14.1
14.3
|
L
 3.5%
H
13.6
14.4
|
L
 1.9%
H
13.0
14.4
|
L
 -5.7%
H
13.0
15.7
|
L
 3.8%
H
12.8
15.7
|
L
 2.7%
H
12.6
17.2
|
L
 -18.0%
H
12.3
20.0
|
L
 -42.9%
H
12.3
30.6
|
| Teva Pharmaceutical Industries |
|
28,211.7
|
24.6
|
L
 -3.2%
H
24.5
25.5
|
L
 2.6%
H
24.0
26.4
|
L
 25.3%
H
18.8
26.4
|
L
 37.7%
H
17.3
26.4
|
L
 49.7%
H
12.5
26.4
|
L
 176.3%
H
7.1
26.4
|
L
 155.3%
H
6.8
26.4
|
L
 -58.2%
H
6.1
66.6
|
| Zoetis |
|
52,354.4
|
118.8
|
L
 -1.7%
H
118.4
121.1
|
L
 -1.2%
H
118.4
123.0
|
L
 -17.1%
H
117.3
148.3
|
L
 -22.9%
H
117.3
160.5
|
L
 -32.2%
H
117.3
181.9
|
L
 -19.9%
H
117.3
201.9
|
L
 -28.1%
H
117.3
249.3
|
L
 162.3%
H
38.3
249.3
|
| Biohaven |
|
1,097.3
|
8.3
|
L
 -0.4%
H
8.0
8.8
|
L
 0.1%
H
7.5
8.8
|
L
 -49.8%
H
7.5
18.6
|
L
 -47.4%
H
7.5
18.6
|
L
 -81.4%
H
7.5
47.8
|
L
 -43.2%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
231.3
|
4.5
|
L
 1.4%
H
4.4
4.6
|
L
 7.4%
H
4.1
5.6
|
L
 -17.6%
H
4
5.6
|
L
 -36.8%
H
4
7.4
|
L
 -23.0%
H
3.9
7.5
|
L
 14.8%
H
2.2
9.0
|
L
 -86.0%
H
2.2
94.8
|
L
 -95.4%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,366.6
|
28.2
|
L
 4.3%
H
26.5
28.4
|
L
 1.7%
H
25.6
30.0
|
L
 6.3%
H
25.1
30.0
|
L
 83.7%
H
14.1
30.0
|
L
 17.4%
H
5.5
30.0
|
L
 18.8%
H
2.2
53.9
|
L
 -41.9%
H
2.2
66
|
L
 -97.4%
H
2.2
1505.5
|
| Acumen Pharmaceuticals Inc |
|
95.7
|
1.6
|
L
 -8.7%
H
1.5
1.7
|
L
 -16.0%
H
1.5
2.0
|
L
 -25.8%
H
1.5
2.5
|
L
 11.3%
H
1.2
2.5
|
L
 -34.2%
H
0.9
2.5
|
L
 -74.3%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
873.2
|
4.5
|
L
 0.4%
H
4.5
4.7
|
L
 0.9%
H
4.4
4.9
|
L
 0.7%
H
4.3
4.9
|
L
 35.1%
H
3.3
5.1
|
L
 24.7%
H
2.7
5.1
|
L
 68.1%
H
1.7
5.1
|
L
 25.1%
H
1.7
6.5
|
L
 -15.6%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
68.3
|
2.9
|
L
 -0.7%
H
2.8
3.1
|
L
 -0.3%
H
2.8
3.1
|
L
 -0.7%
H
2.8
3.1
|
L
 -12.1%
H
2.5
3.4
|
L
 480%
H
0.4
5.5
|
L
 -62.8%
H
0.4
18.7
|
L
 -92.8%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
| Acadia Pharmaceuticals Inc |
|
4,062.1
|
24.0
|
L
 0.0%
H
23.3
24.5
|
L
 6.4%
H
22
24.5
|
L
 16.4%
H
20.3
24.5
|
L
 -5.2%
H
19.7
26.7
|
L
 43.2%
H
13.4
26.7
|
L
 58.1%
H
13.4
33.9
|
L
 -56.0%
H
12.2
57.5
|
L
 -31.2%
H
12.2
58.7
|
| Adicet Bio Inc |
|
90.4
|
0.6
|
L
 -10.6%
H
0.6
0.7
|
L
 -7.8%
H
0.6
0.7
|
L
 -43.3%
H
0.6
1.1
|
L
 -10.6%
H
0.6
1.1
|
L
 -37.9%
H
0.5
1.2
|
L
 -96.6%
H
0.5
20.9
|
L
 -95.3%
H
0.5
21.9
|
L
H
0.5
147.7
|
| Achieve Life Sciences Inc |
|
234.2
|
4.4
|
L
 0.5%
H
4.3
4.5
|
L
 -4.1%
H
4.3
4.9
|
L
 42.9%
H
3.7
5.8
|
L
 72.6%
H
2.5
5.8
|
L
 3.5%
H
1.8
5.8
|
L
 103.7%
H
1.8
10.3
|
L
 -57.5%
H
1.8
16.1
|
L
 -99.9%
H
1.8
6160
|
| AC Immune SA |
|
311.9
|
3.1
|
L
 -5.8%
H
3.1
3.3
|
L
 -6.1%
H
3.1
3.5
|
L
 4.7%
H
2.6
4
|
L
 45.5%
H
2.0
4
|
L
 -2.8%
H
1.4
4
|
L
 21.1%
H
1.4
5.1
|
L
 -38.2%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
265.4
|
2.5
|
L
 -2.8%
H
2.4
2.6
|
L
 5.6%
H
2.1
2.6
|
L
 19.5%
H
1.9
2.7
|
L
 31.0%
H
1.7
2.7
|
L
 19.5%
H
1.1
5.2
|
L
 -86.4%
H
0.6
18.9
|
L
 -23.2%
H
0.6
30.4
|
L
 -86.7%
H
0.6
33.9
|
| Acrivon Therapeutics Inc |
|
74.9
|
2.4
|
L
 6.3%
H
2.2
2.5
|
L
 26.6%
H
1.9
2.5
|
L
 27.3%
H
1.8
2.5
|
L
 76.3%
H
1.3
2.7
|
L
 -65.8%
H
1.1
8
|
L
 -85.8%
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharmaceuticals Inc |
|
22.4
|
1.3
|
L
 5.6%
H
1.3
1.4
|
L
 6.5%
H
1.0
1.4
|
L
 13.8%
H
1.0
1.4
|
L
 214.3%
H
0.4
1.5
|
L
 164%
H
0.4
1.5
|
L
 -45.5%
H
0.4
2.8
|
L
 -95.6%
H
0.4
58.8
|
L
 -98.7%
H
0.4
117.6
|
| Grace Therapeutics Inc |
|
45.5
|
3
|
L
 -2.0%
H
3
3.1
|
L
 0.3%
H
3.0
3.1
|
L
 -6.5%
H
3.0
3.4
|
L
 -8.0%
H
2.9
3.4
|
L
 -3.5%
H
1.8
5.0
|
L
 11.1%
H
1.7
5.1
|
L
 -70%
H
1.7
58.6
|
L
 -97.3%
H
1.7
161.1
|
| Acurx Pharmaceuticals Inc |
|
8.8
|
4.2
|
L
 -8.1%
H
4.2
4.7
|
L
 -10.8%
H
4.2
5.8
|
L
 -40.0%
H
4.2
7.1
|
L
 -17.4%
H
3.8
8.3
|
L
 -87.7%
H
3.8
35.4
|
L
 -93.8%
H
3.8
176.4
|
L
H
3.8
176.4
|
L
H
3.8
176.4
|
| Adial Pharmaceuticals Inc |
|
6.8
|
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
 -6.1%
H
0.3
0.4
|
L
 -16.2%
H
0.3
0.4
|
L
 -20.5%
H
0.3
0.4
|
L
 -70.8%
H
0.2
1.3
|
L
 -95.8%
H
0.2
15
|
L
 -99.3%
H
0.2
127
|
L
H
0.2
236
|
| Adverum Biotechnologies Inc |
|
93.9
|
4.3
|
L
 -0.5%
H
4.2
4.3
|
L
 -1.2%
H
4.2
4.4
|
L
 -6.4%
H
4.0
4.6
|
L
 49.3%
H
2.7
5.8
|
L
 -37.8%
H
1.8
7.7
|
L
 -93.3%
H
1.8
297
|
L
 -99.6%
H
1.8
1479
|
L
 -99.5%
H
1.8
2698
|
| Agios Pharmaceuticals Inc |
|
2,631.7
|
45.1
|
L
 3.4%
H
42.5
46.0
|
L
 11.0%
H
41
46.0
|
L
 8.7%
H
38.9
46.0
|
L
 21.9%
H
32.7
46.0
|
L
 -16.1%
H
23.4
62.5
|
L
 66.3%
H
19.8
62.6
|
L
 13.1%
H
16.8
62.6
|
L
 -23.7%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
467.0
|
1.8
|
L
 5.4%
H
1.7
1.8
|
L
 -13.7%
H
1.6
1.9
|
L
 -39.7%
H
1.6
3.2
|
L
 -45.9%
H
1.6
3.3
|
L
 -1.1%
H
1.5
4.1
|
L
 604%
H
0.2
4.1
|
L
 -32.3%
H
0.2
5.1
|
L
 -79.1%
H
0.2
20.3
|
| Akero Therapeutics Inc |
|
4,473.9
|
54.4
|
L
 0.2%
H
54.2
54.4
|
L
 0.6%
H
54.0
54.4
|
L
 1.3%
H
53.4
54.4
|
L
 10.1%
H
41.8
54.5
|
L
 93.5%
H
21.3
58.4
|
L
 18.8%
H
11.3
58.4
|
L
 98.5%
H
7.5
58.4
|
L
H
7.5
58.4
|
| Aligos Therapeutics Inc |
|
43.2
|
7.0
|
L
 5.4%
H
6.6
7.3
|
L
 -0.7%
H
5.8
7.3
|
L
 -33.2%
H
5.8
10.9
|
L
 -8.8%
H
5.8
11.7
|
L
 -61.1%
H
3.8
46.3
|
L
 -70.9%
H
3.8
60.3
|
L
 -98.7%
H
3.8
937.8
|
L
H
3.8
937.8
|
| Alkermes plc |
|
4,842.9
|
29.3
|
L
 1%
H
29.1
30.3
|
L
 -10.8%
H
27.5
34.5
|
L
 -4.8%
H
27.5
36.3
|
L
 1.0%
H
25.2
36.3
|
L
 4.0%
H
25.2
36.5
|
L
 31.1%
H
22.0
36.5
|
L
 64.4%
H
17.6
36.5
|
L
 -59.9%
H
12.0
80.7
|
| Allarity Therapeutics Inc |
|
16.3
|
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 -2.6%
H
1.1
1.3
|
L
 -22.2%
H
1.1
1.5
|
L
 16.7%
H
0.8
2.1
|
L
 -15.2%
H
0.6
2.1
|
L
 -100.0%
H
0.1
37800
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharmaceuticals Inc |
|
60,843.7
|
460.5
|
L
 2.5%
H
449
463.9
|
L
 4.0%
H
440.9
463.9
|
L
 -4.3%
H
417
495.6
|
L
 2.6%
H
417
495.6
|
L
 95.5%
H
205.9
495.6
|
L
 117.2%
H
142.0
495.6
|
L
 251.4%
H
117.6
495.6
|
L
 354.4%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
31.6
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -23.8%
H
1.2
1.7
|
L
 -4.7%
H
1.2
2.2
|
L
 2.5%
H
1.1
2.2
|
L
 -57.5%
H
1.0
3.5
|
L
 -63.4%
H
1.0
7.4
|
L
 -94.3%
H
1.0
46.6
|
L
H
1.0
309.6
|
| Alzamend Neuro Inc |
|
8.8
|
2.3
|
L
 4.5%
H
2.3
2.4
|
L
 -2.5%
H
2.2
2.5
|
L
 -1.7%
H
2.2
2.7
|
L
 -2.5%
H
2.1
2.7
|
L
 -81.1%
H
2.1
12.9
|
L
 -99.9%
H
2.1
1782
|
L
H
2.1
45292.5
|
L
H
2.1
45292.5
|
| Amylyx Pharmaceuticals Inc |
|
1,535.3
|
14.0
|
L
 10.2%
H
12.6
14.3
|
L
 13.6%
H
11.8
14.3
|
L
 -7.8%
H
11.8
17.0
|
L
 74.8%
H
7.6
17.0
|
L
 193.7%
H
2.6
17.0
|
L
 -60.0%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharmaceuticals Inc |
|
1,195.7
|
26.0
|
L
 -0.2%
H
25.7
26.5
|
L
 8.3%
H
23.8
29
|
L
 12.1%
H
23.1
29
|
L
 -12.8%
H
22.9
31.3
|
L
 -41.7%
H
20.4
46.4
|
L
 -8.0%
H
20.4
67.7
|
L
 33.3%
H
16.9
67.7
|
L
 88.6%
H
10.5
67.7
|
| Anebulo Pharmaceuticals Inc |
|
94.1
|
2.3
|
L
 0.4%
H
2.3
2.4
|
L
 -5.4%
H
2.3
2.5
|
L
 -9.1%
H
2.3
2.9
|
L
 -8.4%
H
1.8
2.9
|
L
 44.0%
H
0.8
3.4
|
L
 -6.5%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| Annexon Inc |
|
437.1
|
3.0
|
L
 11.4%
H
2.7
3.1
|
L
 4.9%
H
2.5
3.1
|
L
 -4.7%
H
2.5
3.6
|
L
 23.8%
H
2.0
3.6
|
L
 -51.1%
H
1.3
6.2
|
L
 -47.7%
H
1.3
8.4
|
L
 -86.7%
H
1.3
38.0
|
L
H
1.3
38.0
|
| Apollomics Inc Ordinary |
|
46.0
|
21.5
|
L
 -12.6%
H
20.0
27.0
|
L
 51.3%
H
13.6
27.0
|
L
 -32.9%
H
10.0
40.0
|
L
 278.3%
H
3.7
42.1
|
L
 123.7%
H
0.1
42.1
|
L
 -97.9%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharmaceuticals Inc |
|
2,543.2
|
20.1
|
L
 -1.1%
H
20.0
20.6
|
L
 4.4%
H
18.9
20.7
|
L
 -16.8%
H
18.8
30.5
|
L
 -27.6%
H
18.8
30.5
|
L
 -23.5%
H
16.1
35.7
|
L
 -54.1%
H
16.1
94.8
|
L
 -47.7%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
40.3
|
0.3
|
L
 27.3%
H
0.2
0.4
|
L
 -67.1%
H
0.2
1.0
|
L
 -77.6%
H
0.2
1.5
|
L
 -41.7%
H
0.2
1.5
|
L
 -96.8%
H
0.2
10.5
|
L
 -67.1%
H
0.2
10.6
|
L
 -98.4%
H
0.2
29.8
|
L
H
0.2
57.4
|
| Aptorum Group Ordinary |
|
11.0
|
1.4
|
L
 -2.2%
H
1.3
1.4
|
L
 -2.2%
H
1.3
1.5
|
L
 -11.2%
H
1.3
1.7
|
L
 -2.9%
H
1.3
4.5
|
L
 98.5%
H
0.5
7.5
|
L
 -79.2%
H
0.5
17.5
|
L
 -93.8%
H
0.5
49.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
6.9
|
1.2
|
L
 -1.7%
H
1.2
1.3
|
L
 -3.3%
H
1.2
1.3
|
L
 -22.7%
H
1.2
1.7
|
L
 -29.6%
H
1.2
1.8
|
L
 -63.4%
H
1.2
5
|
L
 -84.9%
H
1.2
12
|
L
 -99.7%
H
1.2
619.8
|
L
H
1.2
1062.2
|
| Aquestive Therapeutics Inc |
|
710.1
|
5.8
|
L
 8.0%
H
5.4
5.8
|
L
 -3.6%
H
5.2
6.2
|
L
 -17.0%
H
5.2
7.6
|
L
 41.6%
H
3.7
7.6
|
L
 31.1%
H
2.1
7.6
|
L
 465.0%
H
0.7
7.6
|
L
 -6.6%
H
0.6
8.1
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings |
|
192.1
|
6.8
|
L
 -7.0%
H
6.7
7.3
|
L
 -22.5%
H
6.7
9.3
|
L
 -68.9%
H
6.7
24.2
|
L
 -65.3%
H
6.7
24.2
|
L
 -57.8%
H
6.7
24.2
|
L
 -61.3%
H
6.7
45
|
L
 -86.7%
H
6.7
129.7
|
L
 -84.2%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,436.0
|
5.9
|
L
 0.9%
H
5.7
6.0
|
L
 5.7%
H
5.6
6.3
|
L
 17.0%
H
4.9
6.7
|
L
 -1.0%
H
4.7
6.8
|
L
 22.6%
H
3.2
6.8
|
L
 384.4%
H
1.6
10.1
|
L
 1.4%
H
0.5
10.1
|
L
 -67.5%
H
0.5
21.0
|
| Arcutis Biotherapeutics Inc |
|
3,205.6
|
26.2
|
L
 4.7%
H
24.8
26.8
|
L
 8.0%
H
22.3
26.8
|
L
 25.2%
H
19.6
27.1
|
L
 54.9%
H
15.1
27.1
|
L
 182.6%
H
8.9
27.1
|
L
 36.1%
H
1.8
27.1
|
L
 22.2%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
3.6
|
1.8
|
L
 -1.6%
H
1.8
2.0
|
L
 -16.5%
H
1.7
2.2
|
L
 -54.6%
H
1.7
4.3
|
L
 -81.8%
H
1.7
10.6
|
L
 -70.8%
H
1.7
28.6
|
L
 -89.4%
H
1.7
28.6
|
L
 -96.3%
H
1.7
330.3
|
L
H
1.7
15552
|
| Assembly Biosciences Inc |
|
574.6
|
36.3
|
L
 -1.0%
H
35.7
37.7
|
L
 16.4%
H
31.0
37.7
|
L
 24.9%
H
27.1
37.7
|
L
 42.8%
H
20.2
37.7
|
L
 125.1%
H
7.8
37.7
|
L
 129.4%
H
7.7
37.7
|
L
 -46.1%
H
7.7
84.2
|
L
 -66.1%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
800.6
|
7.2
|
L
 -10.7%
H
7.2
7.9
|
L
 -19.6%
H
7.2
9.3
|
L
 -34.5%
H
7.2
11.3
|
L
 -22.2%
H
7.2
14.5
|
L
 -1.1%
H
3.7
14.5
|
L
 214.8%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
72.2
|
0.8
|
L
 -5.1%
H
0.7
0.8
|
L
 -1.3%
H
0.7
1.0
|
L
 -8.5%
H
0.7
1.0
|
L
 -7.4%
H
0.7
1.0
|
L
 -7.4%
H
0.5
1.1
|
L
 -73.3%
H
0.5
8.0
|
L
 -49.3%
H
0.5
8.0
|
L
 -99.0%
H
0.5
108.1
|
| ATAI Life Sciences NV |
|
1,438.2
|
4.0
|
L
 -1%
H
3.9
4.0
|
L
 -9.2%
H
3.9
4.6
|
L
 -27.7%
H
3.9
6.8
|
L
 2.1%
H
3.8
6.8
|
L
 146.0%
H
1.2
6.8
|
L
 38.0%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
197.4
|
12.4
|
L
 -16.8%
H
12.0
14.6
|
L
 -31.1%
H
12.0
19.1
|
L
 -26.0%
H
12.0
24.4
|
L
 -83.3%
H
12.0
73
|
L
 -50.0%
H
6.6
174.6
|
L
 -99.2%
H
6.6
2124.2
|
L
 -99.9%
H
6.6
49571
|
L
H
6.6
49571
|
| Atossa Therapeutics Inc |
|
100.8
|
0.8
|
L
 -2.5%
H
0.8
0.9
|
L
 -4.9%
H
0.8
0.9
|
L
 -24.3%
H
0.8
1.0
|
L
H
0.7
1.3
|
L
 -39.1%
H
0.6
1.4
|
L
 -2.5%
H
0.5
2.3
|
L
 -48.3%
H
0.5
9.8
|
L
 -99.3%
H
0.5
127.8
|
| Atara Biotherapeutics Inc |
|
92.0
|
13.1
|
L
 -4.8%
H
12.8
13.7
|
L
 10.9%
H
11.2
14.3
|
L
 -14.0%
H
10.5
16.2
|
L
 6.6%
H
10.5
16.7
|
L
 9.2%
H
5
18.7
|
L
 -88.5%
H
0.4
141
|
L
 -97.3%
H
0.4
705
|
L
 -98.3%
H
0.4
1361.3
|
| Astria Therapeutics Inc |
|
717.6
|
12.6
|
L
H
12.4
12.6
|
L
 0.5%
H
12.3
12.7
|
L
 4.0%
H
11.8
12.7
|
L
 83.5%
H
6.1
12.7
|
L
 34.2%
H
3.6
12.7
|
L
 49.8%
H
3.6
16.9
|
L
 51.8%
H
2.4
47.8
|
L
 -96.9%
H
2.4
649.8
|
| Atea Pharmaceuticals Inc |
|
235.9
|
3.0
|
L
 2.0%
H
2.9
3.0
|
L
 -7.7%
H
2.9
3.5
|
L
 -3.2%
H
2.9
3.5
|
L
 -13.7%
H
2.8
3.9
|
L
 -6.5%
H
2.5
4.0
|
L
 -37.5%
H
2.5
5.2
|
L
 -90.7%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
306.1
|
16.9
|
L
 11.7%
H
15.0
17.5
|
L
 12.2%
H
14.0
17.5
|
L
 20.6%
H
13.6
19.4
|
L
 87.1%
H
8.4
19.4
|
L
 36.0%
H
3.4
19.4
|
L
 195.6%
H
0.0
34.5
|
L
 -38.2%
H
0.0
54
|
L
 -68.7%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
20.2
|
2.0
|
L
 -5.3%
H
2.0
2.2
|
L
 -2.5%
H
2.0
2.3
|
L
 -14.7%
H
1.8
2.4
|
L
 -10.4%
H
1.7
2.7
|
L
 27.7%
H
1.0
2.8
|
L
 -55%
H
1.0
4.9
|
L
 -99.0%
H
1.0
235.3
|
L
 -100.0%
H
1.0
4272000
|
| Adagene Inc ADR |
|
85.8
|
1.8
|
L
 -0.6%
H
1.8
1.9
|
L
 30%
H
1.4
2.0
|
L
 2.3%
H
1.3
2.0
|
L
 7.7%
H
1.3
3.2
|
L
 -15.7%
H
1.3
3.2
|
L
 78.4%
H
1
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics ADR |
|
7.8
|
8.4
|
L
 -0.8%
H
8.4
8.5
|
L
 -1.2%
H
8.4
9.4
|
L
 -1.5%
H
8.4
12.0
|
L
 5.8%
H
7.5
12.1
|
L
 4.2%
H
6.5
12.1
|
L
 -49.6%
H
5
45.6
|
L
 -96.5%
H
5
700
|
L
H
5
750.4
|
| Amarin Corp ADR |
|
333.5
|
16.0
|
L
 -1.8%
H
15.9
16.5
|
L
 2.1%
H
15.4
16.7
|
L
 -20.1%
H
15.0
20.9
|
L
 2.5%
H
14.5
20.9
|
L
 3108%
H
0.4
20.9
|
L
 1214.8%
H
0.4
20.9
|
L
 242.0%
H
0.4
20.9
|
L
 731.1%
H
0.4
26.1
|
| Ascendis Pharma AS ADR |
|
13,231.4
|
216.6
|
L
 6.0%
H
202.5
223.2
|
L
 9.5%
H
188.1
223.2
|
L
 4.6%
H
186.1
223.2
|
L
 9.2%
H
186.1
223.2
|
L
 71.2%
H
118.0
223.2
|
L
 88.6%
H
64.3
223.2
|
L
 31.7%
H
61.6
223.2
|
L
 1110.5%
H
11.9
223.2
|
| Alterity Therapeutics ADR |
|
68.7
|
3.8
|
L
 -1.3%
H
3.7
3.9
|
L
 9.5%
H
3.5
3.9
|
L
 -21.5%
H
3.4
5.1
|
L
 -27.8%
H
3.4
5.6
|
L
 244.6%
H
1
7
|
L
 -5.0%
H
1
7
|
L
 -86.6%
H
1
27.5
|
L
 -91.9%
H
1
66.9
|
| Avadel Pharmaceuticals plc |
|
2,248.1
|
23.0
|
L
 -2.3%
H
22.9
23.4
|
L
 23.2%
H
18.7
23.6
|
L
 53.5%
H
14.8
23.6
|
L
 68.2%
H
13.4
23.6
|
L
 111%
H
6.4
23.6
|
L
 202.1%
H
5.9
23.6
|
L
 219.3%
H
1.1
23.6
|
L
 55.0%
H
1.0
23.6
|
| Astrazeneca plc ADR |
|
277,188.4
|
89.4
|
L
 0.3%
H
89.1
90.3
|
L
 5.7%
H
85.8
90.3
|
L
 6.6%
H
80.5
90.3
|
L
 12.9%
H
72.9
90.3
|
L
 41.4%
H
61.2
90.3
|
L
 40.1%
H
60.5
90.3
|
L
 58.8%
H
46.5
90.3
|
L
 172.7%
H
25.6
90.3
|
| Biofrontera Inc |
|
9.1
|
0.9
|
L
 3.7%
H
0.8
0.9
|
L
 -21.3%
H
0.8
1.1
|
L
 -14.1%
H
0.8
1.2
|
L
 -8.6%
H
0.8
1.2
|
L
 16.4%
H
0.5
1.9
|
L
 -95.9%
H
0.5
22.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
82.0
|
1.2
|
L
 -9.4%
H
1.2
1.3
|
L
 -15.3%
H
1.2
1.4
|
L
 -27.0%
H
1.2
1.6
|
L
 -33.0%
H
1.2
3.0
|
L
 -82.2%
H
1.2
7.5
|
L
 -84.7%
H
1.2
43.7
|
L
H
1.2
43.7
|
L
H
1.2
43.7
|
| Bolt Biotherapeutics Inc |
|
8.7
|
4.5
|
L
 -1.3%
H
4.4
4.7
|
L
 -0.9%
H
4.4
5.1
|
L
 -23.0%
H
4.4
6.4
|
L
 -12.4%
H
4.4
6.6
|
L
 -60.2%
H
4.4
13
|
L
 -83.5%
H
4.4
40.6
|
L
H
4.4
861.4
|
L
H
4.4
861.4
|
| Blue Water Biotech Inc |
|
41.2
|
2.3
|
L
 0.9%
H
2.2
2.3
|
L
 -15.7%
H
2.2
2.9
|
L
 -33.4%
H
2.2
4
|
L
 -21.2%
H
2.2
4.2
|
L
 2787.5%
H
0.1
5.9
|
L
 89.3%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
82.7
|
2.1
|
L
 -1.9%
H
2.0
2.1
|
L
 4.6%
H
1.9
2.2
|
L
 15.2%
H
1.7
2.4
|
L
 1.5%
H
1.6
2.4
|
L
 26.5%
H
1.0
3.4
|
L
 188.7%
H
0.5
4
|
L
 -87.0%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharmaceuticals Plc |
|
3.4
|
5.5
|
L
 -0.4%
H
5.3
5.7
|
L
 1.1%
H
4.9
5.7
|
L
 -34.5%
H
4.9
8.2
|
L
 -22.4%
H
4.9
11.9
|
L
 -84.9%
H
4.9
92
|
L
 -100.0%
H
4.9
3620042.9
|
L
 -100.0%
H
4.9
38295000
|
L
H
4.9
4045000000
|
| BeiGene ADR |
|
40,121.0
|
376.6
|
L
 3.0%
H
373.3
385.2
|
L
 17.7%
H
327.0
385.2
|
L
 18.4%
H
306
385.2
|
L
 17.2%
H
295.2
385.2
|
L
 99.0%
H
171.0
385.2
|
L
 83.0%
H
127.0
385.2
|
L
 34.5%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx ADR |
|
14.5
|
3.4
|
L
 5.0%
H
3.3
3.4
|
L
 3.7%
H
3.2
3.5
|
L
 -11.3%
H
3.1
3.9
|
L
 -8.6%
H
3.1
4.6
|
L
 -82.2%
H
0.1
22.6
|
L
 -87.4%
H
0.1
101.2
|
L
 -96.2%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc ADR |
|
4,079.1
|
116.9
|
L
 0.2%
H
116.3
121.0
|
L
 3.3%
H
102
124.7
|
L
 31.3%
H
86.5
124.7
|
L
 75.5%
H
60
124.7
|
L
 41.2%
H
49
124.7
|
L
 355.4%
H
11
124.7
|
L
H
6
124.7
|
L
H
6
124.7
|
| Neuphoria Therapeutics Inc |
|
11.1
|
4.7
|
L
 -1.9%
H
4.6
4.8
|
L
 14.6%
H
4.2
5.2
|
L
 -69.0%
H
3.8
17.2
|
L
 -42.0%
H
3.8
21.4
|
L
 1520.7%
H
0.2
21.4
|
L
 -44.7%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
260.1
|
5.7
|
L
 1.6%
H
5.5
6.0
|
L
 -4.1%
H
5.4
6.5
|
L
 -7.6%
H
5.4
7.1
|
L
 -28.5%
H
5.4
8.1
|
L
 -69.4%
H
5.4
20.8
|
L
 43.0%
H
2.7
23.4
|
L
 29.6%
H
2.6
23.4
|
L
 -85.8%
H
0.9
54
|
| CASI Pharmaceuticals Inc |
|
18.4
|
1.2
|
L
 -5.6%
H
1.1
1.3
|
L
 -13.8%
H
1.1
1.5
|
L
 -30%
H
1.1
1.9
|
L
 -50%
H
1.1
2.6
|
L
 -77.7%
H
1.1
5.7
|
L
 -37.0%
H
1.1
8.5
|
L
 -94.0%
H
1.1
39
|
L
 -89.8%
H
1.1
88.9
|
| Cullinan Oncology Inc |
|
518.1
|
8.8
|
L
 2.6%
H
8.4
9.1
|
L
 22.0%
H
7.3
9.1
|
L
 0.3%
H
6.7
9.1
|
L
 14.5%
H
5.7
9.2
|
L
 -36.7%
H
5.7
14.1
|
L
 -29.3%
H
5.7
30.2
|
L
H
5.7
59.9
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
136.6
|
1.1
|
L
 -5.0%
H
1.1
1.2
|
L
 -15.7%
H
1.1
1.4
|
L
 -33.9%
H
1.1
1.8
|
L
 7.6%
H
1.0
1.9
|
L
 54.8%
H
0.7
2.4
|
L
 -84.6%
H
0.7
11.0
|
L
 -93.7%
H
0.7
22.2
|
L
 -95.8%
H
0.7
32.0
|
| Cingulate Inc |
|
18.7
|
3.3
|
L
 -4.6%
H
3.2
3.7
|
L
 -10.7%
H
3.2
3.8
|
L
 -12.4%
H
3.2
4.0
|
L
 -17.6%
H
3.2
4.4
|
L
 -20.7%
H
3.2
6.0
|
L
 254.3%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
86.7
|
8.6
|
L
 1.1%
H
8
8.7
|
L
 -12.0%
H
6.6
10.5
|
L
 4.4%
H
6.6
13.5
|
L
 137.9%
H
3.6
13.5
|
L
 91.3%
H
2.3
13.5
|
L
 -59%
H
2.3
39.8
|
L
 1465.5%
H
0.5
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
9.3
|
2.9
|
L
 0.7%
H
2.7
3.2
|
L
 -13.9%
H
2.7
3.7
|
L
 -38.5%
H
2.7
5.0
|
L
 -32.7%
H
2.7
6.5
|
L
 -94.8%
H
2.7
58.5
|
L
 -94.9%
H
2.7
133.5
|
L
 -99.1%
H
2.7
894
|
L
 -100.0%
H
2.7
47696.2
|
| Clearside Biomedical Inc |
|
17.5
|
3.3
|
L
 -12.6%
H
3.3
3.8
|
L
 -10.2%
H
3.3
4.3
|
L
 -9.7%
H
3.3
4.3
|
L
 -47.3%
H
3.3
6.6
|
L
 -77.5%
H
3.3
17.1
|
L
 -83.5%
H
3.3
31.8
|
L
 -86.7%
H
3.3
116.0
|
L
H
3.3
376.2
|
| Clearmind Medicine Inc |
|
1.8
|
0.3
|
L
H
0.3
0.3
|
L
 -58.8%
H
0.2
0.7
|
L
 -70.5%
H
0.2
1.2
|
L
 -72.8%
H
0.2
1.3
|
L
 -79.1%
H
0.2
2.2
|
L
 -95.0%
H
0.1
6.8
|
L
 -76.5%
H
0.1
21.9
|
L
H
0.1
21.9
|
| Compass Therapeutics Inc |
|
869.7
|
4.9
|
L
 1.2%
H
4.8
5.1
|
L
 15.6%
H
4.1
5.1
|
L
 8.2%
H
3.5
5.1
|
L
 64.7%
H
2.7
5.1
|
L
 254.4%
H
1.3
5.1
|
L
 8.7%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharmaceuticals Inc |
|
3.8
|
6.7
|
L
 -2.9%
H
6.5
6.8
|
L
 2.0%
H
6.0
6.9
|
L
 -29.4%
H
6.0
9.3
|
L
 31.6%
H
5.1
10.6
|
L
 -99.8%
H
4.9
5700
|
L
 -100.0%
H
4.9
9900000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
105.7
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 -8.7%
H
1.0
1.5
|
L
 45.6%
H
0.8
1.6
|
L
 -37.5%
H
0.5
1.8
|
L
 -4.2%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.1
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -7.3%
H
1.0
1.1
|
L
 -4.7%
H
1
1.3
|
L
 -40%
H
1
2.7
|
L
 -52.6%
H
1
3.3
|
L
 -66%
H
1
3.3
|
L
 -90.0%
H
1
41.5
|
L
 -99.6%
H
1
331.2
|
| Collegium Pharmaceutical Inc |
|
1,433.2
|
45.3
|
L
 -1.4%
H
43.6
46.5
|
L
 7.2%
H
42.0
48.2
|
L
 36.5%
H
33.0
48.2
|
L
 20.1%
H
31.3
48.2
|
L
 53.3%
H
23.2
48.2
|
L
 116.1%
H
20.8
48.2
|
L
 138.4%
H
14.0
48.2
|
L
 145.7%
H
7.4
48.2
|
| Corcept Therapeutics Inc |
|
7,901.7
|
75.1
|
L
 -0.6%
H
74.7
76.8
|
L
 1.9%
H
70.7
79.9
|
L
 -5.5%
H
67
80.3
|
L
 4.7%
H
67
91
|
L
 44.9%
H
49
117.3
|
L
 184.4%
H
17.9
117.3
|
L
 315.0%
H
15.8
117.3
|
L
 1468.3%
H
3.2
117.3
|
| Cosmos Health Inc |
|
21.7
|
0.7
|
L
 -2.8%
H
0.7
0.8
|
L
 1.5%
H
0.7
0.8
|
L
 -35.8%
H
0.6
1.1
|
L
 -22.2%
H
0.6
1.3
|
L
 11.1%
H
0.3
1.3
|
L
 -77.4%
H
0.3
23.8
|
L
 -99.4%
H
0.3
225
|
L
 -99.6%
H
0.3
312.5
|
| Cumberland Pharmaceuticals Inc |
|
28.4
|
1.9
|
L
 -10.0%
H
1.9
2.2
|
L
 -10.8%
H
1.9
2.2
|
L
 -44.9%
H
1.9
3.7
|
L
 -39.3%
H
1.9
3.7
|
L
 66.7%
H
1.0
7.3
|
L
 -17.4%
H
1.0
7.3
|
L
 -34.5%
H
1.0
7.5
|
L
 -66.9%
H
1.0
8.0
|
| Catalyst Pharmaceuticals Inc |
|
2,772.9
|
22.6
|
L
 -2.7%
H
22.4
23.2
|
L
 5.5%
H
21.3
23.4
|
L
 9.9%
H
20.3
23.4
|
L
 11.5%
H
19.1
23.4
|
L
 9.5%
H
19.1
26.6
|
L
 48.1%
H
11.1
26.6
|
L
 571.4%
H
3.2
26.6
|
L
 702.8%
H
0.5
26.6
|
| Corbus Pharmaceuticals |
|
197.5
|
11.3
|
L
 1.6%
H
11.0
11.5
|
L
 6.9%
H
10.2
11.5
|
L
 -40.9%
H
9.9
20.6
|
L
 21.6%
H
8.9
20.6
|
L
 -32.3%
H
4.6
20.6
|
L
 189.9%
H
2.1
61.9
|
L
 -69.3%
H
2.1
120
|
L
 -77.9%
H
2.1
323.4
|
| Crinetics Pharmaceuticals Inc |
|
4,129.7
|
43.5
|
L
 2.0%
H
42.0
44.4
|
L
 8.8%
H
39.9
44.4
|
L
 2.9%
H
38.8
44.7
|
L
 41.7%
H
28.7
47.4
|
L
 -20.5%
H
24.1
60.3
|
L
 139.3%
H
15.2
62.5
|
L
 220.2%
H
12.6
62.5
|
L
H
10.6
62.5
|
| Corvus Pharmaceuticals Inc |
|
665.4
|
8.9
|
L
 1.6%
H
8.7
9.2
|
L
 17.2%
H
7.5
9.2
|
L
 16.5%
H
6.8
9.2
|
L
 64.1%
H
5.0
9.2
|
L
 8.8%
H
2.5
9.6
|
L
 879.1%
H
0.6
10
|
L
 116.8%
H
0.6
10
|
L
H
0.6
22.1
|
| CytomX Therapeutics Inc |
|
601.5
|
3.6
|
L
 -8.5%
H
3.5
3.9
|
L
 -1.9%
H
3.5
4.4
|
L
 8.2%
H
3.2
4.6
|
L
 85.9%
H
1.9
4.6
|
L
 290.1%
H
0.4
4.6
|
L
 193.4%
H
0.4
5.9
|
L
 -51.6%
H
0.4
10.1
|
L
 -72.1%
H
0.4
35
|
| CureVac NV |
|
1,188.9
|
5.3
|
L
H
5.3
5.3
|
L
 1.3%
H
5.2
5.4
|
L
 -1.7%
H
5.2
5.4
|
L
 -3.7%
H
5.2
5.5
|
L
 109.5%
H
2.4
5.7
|
L
 -35.4%
H
2.2
12.8
|
L
 -93.8%
H
2.2
151.8
|
L
H
2.2
151.8
|
| Bio Green Med Solution Inc |
|
2.7
|
1.2
|
L
 -7.6%
H
1.2
1.4
|
L
 -20.4%
H
1.2
1.6
|
L
 -68.2%
H
1.2
4.1
|
L
 -84.8%
H
1.2
8.8
|
L
 -98.7%
H
1.2
213.6
|
L
 -100.0%
H
1.2
4212
|
L
 -100.0%
H
1.2
41112
|
L
 -100.0%
H
1.2
907200
|
| Cyclerion Therapeutics Inc |
|
4.5
|
1.4
|
L
 2.2%
H
1.3
1.4
|
L
 -14.2%
H
1.3
1.8
|
L
 -38.2%
H
1.3
2.3
|
L
 -41.1%
H
1.3
3.8
|
L
 -46.1%
H
1.3
8.4
|
L
 -86.0%
H
1.3
19.7
|
L
 -97.5%
H
1.3
138
|
L
H
1.3
457
|
| Cytokinetics Inc |
|
8,185.6
|
67.0
|
L
 0.8%
H
65.3
68.0
|
L
 11.3%
H
60.0
68.0
|
L
 13.6%
H
54.3
68.0
|
L
 73.1%
H
35.2
68.0
|
L
 33.3%
H
29.3
68.0
|
L
 67.1%
H
26.0
110
|
L
 329.4%
H
15.2
110
|
L
 522.2%
H
5.8
110
|
| Cellectis ADR |
|
415.3
|
4.1
|
L
 6.2%
H
4.0
4.3
|
L
 29.8%
H
3.5
4.3
|
L
 -8.4%
H
3.1
4.4
|
L
 45.3%
H
2.5
5.5
|
L
 121.4%
H
1.1
5.5
|
L
 89.0%
H
1.0
5.5
|
L
 -79.4%
H
1.0
34.7
|
L
 -88.0%
H
1.0
38.9
|
| Centessa Pharmaceuticals plc |
|
3,990.8
|
27.3
|
L
 -1.1%
H
27.2
29.3
|
L
 23.5%
H
21.8
29.3
|
L
 19.5%
H
17.1
29.3
|
L
 51.4%
H
15.0
29.3
|
L
 70.8%
H
9.6
29.3
|
L
 694.2%
H
3
29.3
|
L
H
2.9
29.3
|
L
H
2.9
29.3
|
| Connect Biopharma Holdings |
|
138.7
|
2.5
|
L
 17.5%
H
2.1
2.6
|
L
 60.7%
H
1.5
2.6
|
L
 36.1%
H
1.5
2.6
|
L
 21.5%
H
1.2
2.6
|
L
 124.3%
H
0.5
2.9
|
L
 232%
H
0.5
2.9
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
24.4
|
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 -1.1%
H
1.8
2.0
|
L
 -14.6%
H
1.8
2.2
|
L
 -17.7%
H
1.8
2.3
|
L
 -43.6%
H
1.8
9.2
|
L
 -83.9%
H
0.3
16.8
|
L
 -85.9%
H
0.3
46.2
|
L
 -99.5%
H
0.3
519.6
|
| Day One Biopharmaceuticals Inc |
|
907.7
|
8.8
|
L
 0.5%
H
8.5
9.4
|
L
 -9.2%
H
8.5
10.9
|
L
 18.3%
H
6.9
10.9
|
L
 31.0%
H
6.7
10.9
|
L
 -33.6%
H
5.6
14.5
|
L
 -58.3%
H
5.6
25.8
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
208.7
|
7.7
|
L
 -2.5%
H
7.7
8.1
|
L
 -15.6%
H
7.4
9.4
|
L
 3.9%
H
7.1
9.4
|
L
 10.7%
H
6.7
9.4
|
L
 49.0%
H
3.5
9.4
|
L
 282.6%
H
1.0
9.4
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharmaceuticals Inc |
|
-
|
8.2
|
L
 6.9%
H
7.9
8.6
|
L
 18.6%
H
6.6
8.6
|
L
 8.0%
H
6.6
8.6
|
L
 -18.9%
H
6.6
11.3
|
L
 -6.5%
H
5.5
13.1
|
L
 -11.4%
H
4.1
14.4
|
L
 -83.4%
H
4.1
138.8
|
L
 -99.9%
H
4.1
29250
|
| DiaMedica Therapeutics Inc |
|
333.8
|
6.4
|
L
 8.1%
H
5.8
6.7
|
L
 8.3%
H
5.3
6.7
|
L
 -4.0%
H
5.3
7.2
|
L
 6.3%
H
5.1
7.5
|
L
 59.9%
H
3.2
7.5
|
L
 429.8%
H
1.1
7.5
|
L
 53.0%
H
1.1
10.9
|
L
 232.1%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
1.9
|
2.8
|
L
 -7.5%
H
2.7
3.1
|
L
 -6.6%
H
2.7
3.3
|
L
 -28.8%
H
2.7
4.4
|
L
 -52.5%
H
2.7
6.2
|
L
 153.6%
H
0.6
7.1
|
L
 -75.9%
H
0.2
11.8
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Technologies ADR |
|
484.6
|
13.5
|
L
 1.8%
H
13.2
14.3
|
L
 -3.5%
H
12.6
14.7
|
L
 -20.7%
H
12.6
17.9
|
L
 34.9%
H
8.7
18
|
L
 357.0%
H
0.5
18
|
L
 2.1%
H
0.5
23.7
|
L
 -45.9%
H
0.5
73.8
|
L
 -96.0%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
12.8
|
1.7
|
L
H
1.7
1.8
|
L
 1.8%
H
1.7
1.8
|
L
 -29.3%
H
1.7
3.0
|
L
 -22.3%
H
1.7
3.0
|
L
 -17.1%
H
1.6
4.5
|
L
 -71.4%
H
1.6
19.7
|
L
 -95.1%
H
1.6
84
|
L
 -99.9%
H
1.6
2516.6
|
| Eledon Pharmaceuticals Inc |
|
121.6
|
1.6
|
L
 -8.0%
H
1.6
1.8
|
L
 -21.4%
H
1.6
2.4
|
L
 -43.2%
H
1.4
4.6
|
L
 -38.4%
H
1.4
4.6
|
L
 -59.0%
H
1.4
5.1
|
L
 -38.4%
H
1.1
5.4
|
L
 -92.5%
H
1.1
26.4
|
L
 -99.9%
H
1.1
1931.0
|
| Enanta Pharmaceuticals Inc |
|
369.9
|
12.8
|
L
 6.3%
H
11.9
12.9
|
L
 16.7%
H
11
12.9
|
L
 12.7%
H
10.2
12.9
|
L
 60.3%
H
7.1
15.3
|
L
 32.4%
H
4.1
15.3
|
L
 -72.1%
H
4.1
62.1
|
L
 -71.7%
H
4.1
102
|
L
 -56.7%
H
4.1
127.8
|
| Entera Bio |
|
122.4
|
2.7
|
L
 -1.1%
H
2.7
2.8
|
L
 -14.7%
H
2.6
3.2
|
L
 11.2%
H
2.1
3.2
|
L
 34%
H
1.8
3.2
|
L
 54.9%
H
1.5
3.2
|
L
 332.3%
H
0.5
3.4
|
L
 141.4%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Evolus Inc |
|
450.5
|
7.0
|
L
 -3.7%
H
6.9
7.3
|
L
 6.0%
H
6.6
7.7
|
L
 10.3%
H
6.1
7.8
|
L
 3.3%
H
5.8
8.0
|
L
 -42.6%
H
5.7
17.1
|
L
 -10.3%
H
5.7
17.8
|
L
 93.6%
H
3.1
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
814.3
|
2.9
|
L
 11.2%
H
2.5
2.9
|
L
 26.4%
H
2.2
2.9
|
L
 13.4%
H
2.1
2.9
|
L
 75%
H
1.3
2.9
|
L
 7.5%
H
1.0
3.3
|
L
 -61.7%
H
1.0
8.2
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
668.5
|
2.8
|
L
 -2.8%
H
2.7
2.9
|
L
 6.0%
H
2.7
3.3
|
L
 6.4%
H
2.4
3.3
|
L
 37.6%
H
2
3.4
|
L
 33.0%
H
0.7
3.9
|
L
 -61.4%
H
0.7
8.9
|
L
 -90.6%
H
0.7
39.5
|
L
 -89.5%
H
0.7
82.7
|
| Eton Pharmaceuticals Inc |
|
462.9
|
17.3
|
L
 1.9%
H
17.0
17.8
|
L
 2.1%
H
16.5
18.2
|
L
 -5.9%
H
16.3
20.0
|
L
 1.3%
H
15.6
23
|
L
 72.3%
H
9.8
23
|
L
 455.0%
H
2.4
23
|
L
 132.3%
H
2.0
23
|
L
H
2.0
23
|
| Evoke Pharma Inc |
|
18.4
|
10.7
|
L
H
10.7
10.8
|
L
H
10.6
10.8
|
L
 136.5%
H
4.4
10.8
|
L
 108.8%
H
4.2
10.8
|
L
 133.4%
H
1.9
10.8
|
L
 -45.7%
H
0.4
71.5
|
L
 -97.9%
H
0.4
691.2
|
L
 -97.7%
H
0.4
1599.8
|
| Exelixis Inc |
|
11,373.3
|
42.4
|
L
 1.9%
H
41.6
43.2
|
L
 4.0%
H
39.8
43.7
|
L
 8.2%
H
33.8
43.7
|
L
 10.7%
H
33.8
43.7
|
L
 23.1%
H
31.9
49.6
|
L
 151.8%
H
15.3
49.6
|
L
 115.9%
H
14.9
49.6
|
L
 674.1%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
42.0
|
4.3
|
L
 -15.2%
H
4.1
4.8
|
L
 -34.0%
H
4.1
6.3
|
L
 -37.6%
H
4.1
9.1
|
L
 -41.0%
H
4.1
15
|
L
 -47.9%
H
0.0
18.0
|
L
 -97.1%
H
0.0
468
|
L
 -98.5%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharmaceuticals Inc |
|
1,087.8
|
13.1
|
L
 13.5%
H
11.6
13.3
|
L
 17.2%
H
11.2
13.3
|
L
 13.8%
H
9.7
13.3
|
L
 18.5%
H
9.7
14.9
|
L
 43.3%
H
3.9
14.9
|
L
 221.3%
H
2.2
31.0
|
L
 209.9%
H
2.2
31.0
|
L
 -65.2%
H
2.2
58.1
|
| Evotec SE ADR |
|
1,051.4
|
3.0
|
L
 -2.0%
H
2.9
3.0
|
L
 -3.9%
H
2.9
3.2
|
L
 -26%
H
2.9
4.3
|
L
 -21.3%
H
2.9
4.3
|
L
 -45.4%
H
2.8
5.6
|
L
 -66.2%
H
2.8
13.5
|
L
 -79.9%
H
2.8
26.6
|
L
 36.4%
H
1.6
26.6
|
| Fortress Biotech Inc |
|
77.7
|
2.6
|
L
 -0.4%
H
2.5
2.7
|
L
H
2.4
2.7
|
L
 -4.7%
H
2.4
2.9
|
L
 23.1%
H
2.0
4.2
|
L
 82.5%
H
1.3
4.2
|
L
 -80.2%
H
1.2
17.4
|
L
 -93.5%
H
1.2
91.5
|
L
 -94.4%
H
1.2
91.5
|
| Fennec Pharmaceuticals Inc |
|
243.5
|
8.8
|
L
 11.3%
H
8.0
9
|
L
 9.7%
H
7.5
9
|
L
 1.3%
H
7.5
9.2
|
L
 4.7%
H
7.5
9.9
|
L
 119.3%
H
4.0
9.9
|
L
 9.5%
H
4.0
11.9
|
L
 6.7%
H
3.8
11.9
|
L
 534.1%
H
0.3
15.0
|
| FibroGen Inc |
|
35.2
|
8.7
|
L
 0.1%
H
8.5
9.1
|
L
 -21.1%
H
8.3
11.2
|
L
 -19.3%
H
8.3
11.7
|
L
 -8.4%
H
8.3
12.6
|
L
 3.8%
H
4.9
22.0
|
L
 -97.7%
H
4.5
642.3
|
L
 -99.2%
H
4.5
1430.2
|
L
 -98.7%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
27.9
|
2.3
|
L
 6.0%
H
2.2
2.4
|
L
 1.3%
H
2.1
2.5
|
L
 -36.4%
H
2.1
3.6
|
L
 16.2%
H
1.6
4.0
|
L
 -93.1%
H
1.3
33.9
|
L
 -93.8%
H
1.3
53.8
|
L
 -98.7%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Amicus Therapeutics Inc |
|
2,906.4
|
9.4
|
L
 -0.6%
H
9.4
9.6
|
L
 6.2%
H
8.8
9.6
|
L
 16.2%
H
7.9
9.6
|
L
 27.3%
H
7.3
9.6
|
L
 -2.7%
H
5.5
10.4
|
L
 -14.4%
H
5.5
14.6
|
L
 -58.4%
H
5.5
25.4
|
L
 -7.0%
H
4.4
25.4
|
| Fulcrum Therapeutics Inc |
|
522.2
|
9.7
|
L
 11.6%
H
8.5
9.8
|
L
 26.5%
H
7.5
9.8
|
L
 3.9%
H
7.3
10.1
|
L
 41.5%
H
6.4
10.1
|
L
 221.7%
H
2.3
10.1
|
L
 33.1%
H
2.3
15
|
L
 -19.9%
H
2.3
33.1
|
L
H
2.3
33.1
|
| Generation Bio Co |
|
36.4
|
5.4
|
L
 -0.4%
H
5.4
5.7
|
L
 5.7%
H
5.2
5.9
|
L
 -18.7%
H
4.9
6.5
|
L
 -14.2%
H
4.9
6.9
|
L
 -66.5%
H
3
16.8
|
L
 -91.2%
H
3
73.5
|
L
 -98.4%
H
3
557.2
|
L
H
3
557.2
|
| GH Research PLC |
|
874.6
|
14.1
|
L
 0.7%
H
13.1
14.3
|
L
 4.4%
H
13.1
15.3
|
L
 2.0%
H
12.4
15.3
|
L
 10.2%
H
11.8
15.3
|
L
 55.1%
H
6.7
20.5
|
L
 30.7%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharmaceuticals |
|
5.8
|
1.1
|
L
 1.0%
H
1.0
1.5
|
L
 -12.5%
H
1.0
1.5
|
L
 -25.5%
H
1.0
1.5
|
L
 -27.1%
H
1.0
1.7
|
L
 -64.2%
H
1.0
3.6
|
L
 -98.2%
H
0.2
170.1
|
L
 -99.8%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
30.3
|
22.9
|
L
 -14.8%
H
21.3
27.9
|
L
 361.6%
H
15
33.6
|
L
 107.9%
H
5.0
33.6
|
L
 576.0%
H
2.5
33.6
|
L
 259.3%
H
2.0
33.6
|
L
 1205.7%
H
0.5
33.6
|
L
 36.2%
H
0.5
33.6
|
L
H
0.5
33.6
|
| GlycoMimetics Inc |
|
843.4
|
13.1
|
L
 0.4%
H
12.9
13.2
|
L
 -0.5%
H
12.7
13.5
|
L
 5.8%
H
11.7
13.5
|
L
 -5.2%
H
9.8
15.8
|
L
 -68.6%
H
9.8
44.8
|
L
 -93.0%
H
9.8
416
|
L
 -96.5%
H
9.8
440
|
L
 -98.1%
H
9.8
2605
|
| Genelux Corp |
|
199.8
|
5.3
|
L
 -1.3%
H
5
5.8
|
L
 -3.1%
H
5
6.3
|
L
 -2.1%
H
4.3
8.5
|
L
 47.5%
H
3.3
8.5
|
L
 122.5%
H
2.0
8.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
6.6
|
4.0
|
L
 -8.8%
H
4.0
4.5
|
L
 -4.0%
H
3.9
5
|
L
 741.7%
H
0.3
13.0
|
L
 1823.8%
H
0.1
13.0
|
L
 152.5%
H
0.1
13.0
|
L
 208.4%
H
0.1
13.0
|
L
 23.9%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
692.1
|
3.0
|
L
 10.3%
H
2.7
3.1
|
L
 26.7%
H
2.4
3.1
|
L
 29.4%
H
2.1
3.1
|
L
 52.6%
H
1.9
3.6
|
L
 304.1%
H
0.7
3.6
|
L
 -67.6%
H
0.5
9.6
|
L
 -67.4%
H
0.5
15.2
|
L
H
0.5
27.2
|
| GT Biopharma Inc |
|
7.3
|
0.7
|
L
 -25%
H
0.7
0.8
|
L
 11.3%
H
0.6
1.2
|
L
 1.5%
H
0.5
1.2
|
L
 -48.5%
H
0.5
1.5
|
L
 -76.4%
H
0.5
4.1
|
L
 -65.8%
H
0.2
10.7
|
L
 -78.0%
H
0.2
19.7
|
L
 -100.0%
H
0.2
30600
|
| Genmab ADR |
|
18,728.8
|
30.4
|
L
 0.5%
H
30.3
30.9
|
L
 6.1%
H
28.9
30.9
|
L
 -7.1%
H
28.1
33.2
|
L
 30.5%
H
23.2
33.7
|
L
 47.7%
H
17.2
33.7
|
L
 -30.1%
H
17.2
47.5
|
L
 -14.3%
H
17.2
49.1
|
L
 149.3%
H
9.2
49.1
|
| Genfit ADR |
|
230.5
|
4.6
|
L
 8.5%
H
4.3
4.6
|
L
 18.5%
H
4.0
4.6
|
L
 10.8%
H
3.6
4.6
|
L
 15.5%
H
3.4
4.6
|
L
 2.4%
H
2.6
4.8
|
L
 16.1%
H
2.6
6.4
|
L
 -5.5%
H
2.6
7.2
|
L
H
2.6
26.3
|
| Genenta Science SpA ADR |
|
48.3
|
2.1
|
L
 -5.1%
H
2.1
2.2
|
L
 -10.4%
H
2.1
2.4
|
L
 -35.8%
H
2.1
10
|
L
 -41.1%
H
2.1
10
|
L
 -59.0%
H
2.1
10
|
L
 -51.0%
H
2.1
10
|
L
H
2.1
13.1
|
L
H
2.1
13.1
|
| Grifols SA ADR Level III |
|
5,784.3
|
8.5
|
L
 -2.4%
H
8.5
8.7
|
L
 0.7%
H
8.5
8.9
|
L
 -12.8%
H
8.2
9.9
|
L
 -20.7%
H
8.2
10.7
|
L
 -10.2%
H
6.2
11.1
|
L
 7.6%
H
5.3
12.2
|
L
 -55.8%
H
5.3
20.5
|
L
 -51.5%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
15.5
|
1.2
|
L
 -1.7%
H
1.2
1.2
|
L
 -4.9%
H
1.1
1.3
|
L
 -18.2%
H
1.1
1.5
|
L
 -8.6%
H
1.1
2.1
|
L
 42.7%
H
0.7
3.8
|
L
 -69.0%
H
0.6
12.5
|
L
 -97.3%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
44.7
|
0.9
|
L
H
0.9
1
|
L
 -20%
H
0.9
1.2
|
L
 -44.9%
H
0.9
1.8
|
L
 -30.8%
H
0.9
2.4
|
L
 -48.0%
H
0.6
2.4
|
L
 -50.8%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
| Harmony Biosciences Holdings |
|
1,957.7
|
34.0
|
L
 -0.1%
H
33.7
34.8
|
L
 8.2%
H
31.1
34.8
|
L
 31.0%
H
25.5
34.8
|
L
 -7.8%
H
25.5
38.3
|
L
 3.8%
H
25.5
40.9
|
L
 -38.9%
H
18.6
62.1
|
L
 -20.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,492.2
|
40.3
|
L
 -1.2%
H
39.5
41.6
|
L
 18.7%
H
32.6
41.6
|
L
 6.3%
H
32.6
42.4
|
L
 3.8%
H
32.6
50.7
|
L
 3.3%
H
20.9
50.7
|
L
 285.6%
H
7.6
59.2
|
L
 491.6%
H
5.1
59.2
|
L
 640.6%
H
1.4
59.2
|
| HUTCHMED China ADR |
|
2,531.6
|
14.7
|
L
 -2.3%
H
14.6
15.0
|
L
 -1.5%
H
14.6
15.4
|
L
 -4.4%
H
14.4
15.8
|
L
 -10.5%
H
14.4
18.3
|
L
 -12.0%
H
11.5
19.5
|
L
 30.7%
H
9.8
21.9
|
L
 -51.6%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
1,999.5
|
2.0
|
L
 -2.4%
H
2
2.1
|
L
 -4.7%
H
2.0
2.2
|
L
 -19.8%
H
2.0
2.7
|
L
 -20.4%
H
2.0
3.0
|
L
 -54.8%
H
1.8
5.4
|
L
 -64.3%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
2,922.8
|
33.3
|
L
 3.7%
H
31.7
34.6
|
L
 10.3%
H
30.3
34.6
|
L
 20.4%
H
26.9
34.6
|
L
 37.0%
H
23.2
34.6
|
L
 25.2%
H
13.5
34.6
|
L
 87.9%
H
13.3
47.7
|
L
 147.3%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
113.3
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 1.3%
H
1.5
1.7
|
L
 0.7%
H
1.3
1.8
|
L
 -13.1%
H
1.3
1.9
|
L
 -24.8%
H
1.3
4.2
|
L
 -59.0%
H
0.8
6.9
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
135.7
|
4.0
|
L
 -4.0%
H
3.9
4.6
|
L
 28.3%
H
3.2
4.6
|
L
 49.6%
H
2.7
4.6
|
L
 78.0%
H
1.9
4.6
|
L
 154.1%
H
1.3
4.6
|
L
 248.3%
H
1.0
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immuneering Corp Ordinary |
|
446.8
|
6.9
|
L
 9.0%
H
6.3
7.0
|
L
 0.4%
H
6
7.6
|
L
 24.9%
H
5.2
7.6
|
L
 84.0%
H
3.3
10.1
|
L
 284.4%
H
1.1
10.1
|
L
 0.6%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
87.8
|
0.7
|
L
 -6.4%
H
0.7
0.8
|
L
 1.4%
H
0.7
0.8
|
L
 -11.0%
H
0.7
0.9
|
L
 -18.9%
H
0.7
1.1
|
L
 -31.1%
H
0.6
1.4
|
L
 -48.6%
H
0.6
3.2
|
L
 -96.0%
H
0.6
28.2
|
L
 -99.8%
H
0.6
472
|
| Incyte |
|
20,450.9
|
104.2
|
L
 0.0%
H
103.8
106.0
|
L
 -1.7%
H
103.8
109.3
|
L
 19.3%
H
84.0
109.3
|
L
 19.9%
H
81.1
109.3
|
L
 37.3%
H
53.6
109.3
|
L
 35.8%
H
50.3
109.3
|
L
 23.5%
H
50.3
109.3
|
L
 -3.6%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
2.5
|
2.3
|
L
 -9.6%
H
2.3
2.6
|
L
 -10.6%
H
2.3
3.2
|
L
 -33.8%
H
2.3
4
|
L
 -68.1%
H
2.2
8.6
|
L
 104.5%
H
0.3
13.4
|
L
 36.7%
H
0.3
13.4
|
L
 -83.5%
H
0.3
36.8
|
L
 -99.5%
H
0.3
8800
|
| Indivior Plc |
|
3,917.9
|
31.4
|
L
 2.9%
H
30.1
31.4
|
L
 0.1%
H
29.4
31.4
|
L
 27.1%
H
23.7
32.4
|
L
 33.8%
H
22.2
32.4
|
L
 219.6%
H
7.6
32.4
|
L
 59.8%
H
3.1
32.4
|
L
 1813.4%
H
1.2
32.4
|
L
 960.1%
H
0.4
32.4
|
| InMed Pharmaceuticals Inc |
|
4.6
|
1.7
|
L
 -2.9%
H
1.7
1.7
|
L
 3.1%
H
1.6
1.9
|
L
 -20.7%
H
1.6
2.2
|
L
 -28.9%
H
1.6
2.5
|
L
 -63.7%
H
1.6
8.3
|
L
 -97.8%
H
1.6
92.6
|
L
 -99.9%
H
1.6
3210
|
L
 -99.9%
H
1.6
32175
|
| Inovio Pharmaceuticals Inc |
|
136.0
|
2.0
|
L
 -3.4%
H
2.0
2.1
|
L
 -6.6%
H
1.9
2.2
|
L
 -19.5%
H
1.9
2.7
|
L
 6.5%
H
1.8
3.0
|
L
 -53.5%
H
1.3
4.6
|
L
 -15.4%
H
0.3
14.8
|
L
 -84.6%
H
0.3
19
|
L
 -71.5%
H
0.3
33.8
|
| Insmed Inc |
|
42,100.2
|
197.4
|
L
 2.2%
H
191.8
197.9
|
L
 4.1%
H
185.7
197.9
|
L
 21.0%
H
154.8
197.9
|
L
 54.5%
H
126
197.9
|
L
 197.8%
H
60.4
197.9
|
L
 994.8%
H
16.0
197.9
|
L
 438.0%
H
16.0
197.9
|
L
 1143.9%
H
9.0
197.9
|
| Innoviva Inc |
|
1,642.7
|
22.0
|
L
 -1.3%
H
22.0
22.5
|
L
 5.3%
H
20.3
22.8
|
L
 27.4%
H
17.1
22.8
|
L
 5.0%
H
16.5
22.8
|
L
 16.2%
H
16.5
22.8
|
L
 66.9%
H
10.6
22.8
|
L
 102.3%
H
10.2
22.8
|
L
 144.4%
H
7.6
22.8
|
| Ionis Pharmaceuticals Inc |
|
11,866.2
|
73.3
|
L
 2.4%
H
70.7
74.4
|
L
 -0.4%
H
66.7
74.5
|
L
 0.3%
H
66.7
76.8
|
L
 67.3%
H
41.8
76.8
|
L
 113.3%
H
24.0
76.8
|
L
 71.6%
H
24.0
76.8
|
L
 40.5%
H
24.0
76.8
|
L
 21.6%
H
19.6
86.6
|
| Ironwood Pharmaceuticals Inc |
|
509.2
|
3.1
|
L
 -0.3%
H
3.0
3.5
|
L
 63.0%
H
2.3
3.5
|
L
 101.9%
H
1.4
3.5
|
L
 203.9%
H
1.0
3.5
|
L
 -25.7%
H
0.5
5.1
|
L
 -72.2%
H
0.5
15.7
|
L
 -73.5%
H
0.5
15.7
|
L
 -68.9%
H
0.5
17.7
|
| Iterum Therapeutics Plc |
|
17.3
|
0.4
|
L
 -23.4%
H
0.4
0.5
|
L
 -40%
H
0.4
0.6
|
L
 -48.6%
H
0.4
0.8
|
L
 -58.1%
H
0.4
0.9
|
L
 -73.7%
H
0.4
3.0
|
L
 -74.8%
H
0.4
3.0
|
L
 -95.3%
H
0.4
44.9
|
L
H
0.4
195
|
| IMab ADR |
|
503.7
|
4.4
|
L
 5.3%
H
4.0
4.4
|
L
 9.3%
H
4.0
4.4
|
L
 -33.4%
H
3.8
6.4
|
L
 -10.3%
H
3.2
6.8
|
L
 320.2%
H
0.6
6.8
|
L
 0.5%
H
0.6
7.7
|
L
 -88.3%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron ADR |
|
10.8
|
1.6
|
L
 -1.3%
H
1.6
1.6
|
L
 -4.9%
H
1.5
1.7
|
L
 -29.1%
H
1.4
2.4
|
L
 -13.8%
H
1.4
2.4
|
L
 -13.8%
H
1.4
2.5
|
L
 -22%
H
1.4
6.0
|
L
 -78.4%
H
1.4
9.2
|
L
H
1.4
29.0
|
| Innate Pharma ADR |
|
167.7
|
1.8
|
L
H
1.8
1.8
|
L
 2.3%
H
1.8
2.4
|
L
 -15.0%
H
1.7
2.4
|
L
 -16.9%
H
1.7
2.4
|
L
 26.4%
H
1.3
3.5
|
L
 -19.5%
H
1.3
4.0
|
L
 -60.3%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Jaguar Health Inc |
|
6.7
|
1.8
|
L
 1.1%
H
1.8
2.0
|
L
 1.1%
H
1.6
2.0
|
L
 -15.1%
H
1.6
2.2
|
L
 -14.3%
H
1.6
2.4
|
L
 87.5%
H
0.4
15.5
|
L
 -99.7%
H
0.4
684
|
L
 -99.9%
H
0.4
60345
|
L
 -100.0%
H
0.4
999999
|
| Jazz Pharmaceuticals plc |
|
10,335.5
|
170.1
|
L
 20.6%
H
162.6
172.9
|
L
 29.7%
H
132.1
172.9
|
L
 26.7%
H
128.8
172.9
|
L
 44.4%
H
117.1
172.9
|
L
 40.7%
H
95.5
172.9
|
L
 19.2%
H
95.5
172.9
|
L
 16.5%
H
95.5
189
|
L
 23.8%
H
86.9
189
|
| Kala Pharmaceuticals Inc |
|
4.9
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -1.4%
H
0.6
0.8
|
L
 -49.3%
H
0.6
1.4
|
L
 -91.6%
H
0.6
20.6
|
L
 -89.6%
H
0.6
20.6
|
L
 -89.2%
H
0.6
56.7
|
L
 -99.8%
H
0.6
498.5
|
L
H
0.6
1337.5
|
| KalVista Pharmaceuticals Inc |
|
751.1
|
14.9
|
L
 9.1%
H
13.3
15.0
|
L
 37.9%
H
10.6
15.0
|
L
 34.6%
H
10.4
15.0
|
L
 15.4%
H
10.4
17.3
|
L
 56.6%
H
7.3
17.3
|
L
 178.8%
H
5.0
17.3
|
L
 -21.1%
H
4.1
45
|
L
 -72.4%
H
4.1
58.0
|
| Kiniksa Pharmaceuticals |
|
3,137.9
|
41.4
|
L
 2.7%
H
39.6
41.7
|
L
 7.9%
H
38.6
41.7
|
L
 6.4%
H
35.2
42.1
|
L
 24.0%
H
32.9
42.1
|
L
 94.5%
H
17.8
42.1
|
L
 161.2%
H
10.3
42.1
|
L
 160.1%
H
7.4
42.1
|
L
H
5.0
42.1
|
| Kiora Pharmaceuticals Inc |
|
7.7
|
2.1
|
L
 -3.2%
H
2.1
2.2
|
L
 -10.3%
H
2.1
2.4
|
L
 -22.6%
H
2.1
2.7
|
L
 -28.7%
H
2.1
3.0
|
L
 -36.1%
H
2.1
4.2
|
L
 -64.6%
H
0.4
8.5
|
L
 -98.5%
H
0.4
327.2
|
L
 -99.9%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
98.7
|
5.8
|
L
 1.9%
H
5.5
6.1
|
L
 12.2%
H
5.1
6.1
|
L
 -4.0%
H
5.0
6.8
|
L
 -2.2%
H
4.5
8.2
|
L
 -52.6%
H
0.6
13.2
|
L
 -92.7%
H
0.6
81.3
|
L
 -97.6%
H
0.6
270
|
L
 -97.6%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
529.2
|
17.4
|
L
 0.6%
H
16.7
17.6
|
L
 7.2%
H
16.3
17.6
|
L
 26.4%
H
13.6
17.6
|
L
 20.0%
H
13.6
17.6
|
L
 -69.3%
H
9.1
72.4
|
L
 -60.4%
H
9.1
73
|
L
 -74.5%
H
9.1
88.8
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
5.4
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 5.8%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
 4.3%
H
0.7
0.9
|
L
 -78.4%
H
0.7
3.9
|
L
 -27%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics ADR |
|
10.2
|
6.1
|
L
 -3.0%
H
5.8
6.7
|
L
 -17.1%
H
5.8
8.0
|
L
 -13.0%
H
5.8
8.0
|
L
 -24.4%
H
5.8
8.9
|
L
 -73.4%
H
2.9
30.1
|
L
 -81.9%
H
2.9
84
|
L
 -98.7%
H
2.9
792.5
|
L
 -98.8%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
22.4
|
1.0
|
L
 -4.7%
H
1.0
1.1
|
L
 -2.9%
H
1.0
1.2
|
L
 23.2%
H
0.8
1.2
|
L
 23.2%
H
0.8
1.6
|
L
 -50.5%
H
0.8
2.9
|
L
 -56.3%
H
0.7
6.9
|
L
 -83.9%
H
0.7
12.5
|
L
 -81.5%
H
0.7
76.2
|
| Lifecore Biomedical Inc |
|
296.0
|
7.9
|
L
 -0.8%
H
7.8
8.1
|
L
 15.3%
H
6.7
8.5
|
L
 21.0%
H
6.4
8.5
|
L
 7.2%
H
6.3
8.7
|
L
 23.4%
H
4.8
8.9
|
L
 -11.9%
H
1.5
11.5
|
L
 -22.6%
H
1.5
12.9
|
L
 -35.1%
H
1.5
15.6
|
| Ligand Pharmaceuticals Inc |
|
3,962.9
|
201.4
|
L
 0.2%
H
200.8
207.3
|
L
 -0.6%
H
198.5
212.5
|
L
 11.4%
H
179
212.5
|
L
 33.3%
H
149.5
212.5
|
L
 80.2%
H
93.6
212.5
|
L
 152.7%
H
49.3
212.5
|
L
 280.6%
H
46.8
212.5
|
L
 212.7%
H
36.9
212.5
|
| Atyr Pharma Inc |
|
66.6
|
0.7
|
L
 -9.3%
H
0.7
0.8
|
L
 -17.1%
H
0.7
0.8
|
L
 -32%
H
0.7
1.1
|
L
 -86.1%
H
0.7
6.5
|
L
 -76.6%
H
0.7
7.3
|
L
 -71.4%
H
0.7
7.3
|
L
 -79.5%
H
0.7
13.1
|
L
 -99.5%
H
0.7
153.0
|
| Lipocine Inc |
|
16.3
|
3
|
L
 4.5%
H
2.9
3.1
|
L
 18.1%
H
2.6
3.1
|
L
 -3.5%
H
2.5
3.1
|
L
 -1.0%
H
2.5
3.5
|
L
 -38.7%
H
2.5
5.5
|
L
 -58.0%
H
2.3
11.8
|
L
 -87.4%
H
2.3
41.1
|
L
 -98.8%
H
2.3
249.7
|
| Liquidia Corp |
|
2,470.7
|
28.4
|
L
 1.3%
H
27.7
29.0
|
L
 8.9%
H
26.4
29.2
|
L
 22.5%
H
21.9
29.2
|
L
 9.4%
H
21.1
29.9
|
L
 188.6%
H
9.7
29.9
|
L
 495.4%
H
4.5
29.9
|
L
 684.5%
H
2.3
29.9
|
L
H
2.3
38.5
|
| Lisata Therapeutics Inc |
|
18.4
|
2.1
|
L
 -1.4%
H
2.0
2.3
|
L
 1.5%
H
1.9
2.3
|
L
 -17.1%
H
1.9
3.0
|
L
 -17.4%
H
1.9
3.0
|
L
 -26.7%
H
1.9
4.2
|
L
 -49.8%
H
1.9
4.5
|
L
 -90.6%
H
1.9
73.4
|
L
 -98.8%
H
1.9
207
|
| Lantern Pharma Inc |
|
36.3
|
3.4
|
L
 -0.6%
H
3.2
3.6
|
L
 -1.8%
H
3.2
3.7
|
L
 -22.2%
H
3.0
4.3
|
L
 -26.5%
H
3.0
4.8
|
L
 -5.1%
H
2.6
6.1
|
L
 -39.8%
H
2.4
12.0
|
L
 -78.8%
H
2.4
23.5
|
L
H
2.4
24.8
|
| Lexicon Pharmaceuticals Inc |
|
530.6
|
1.5
|
L
 -2.0%
H
1.4
1.5
|
L
 16.8%
H
1.3
1.6
|
L
 -0.7%
H
1.2
1.6
|
L
 17.7%
H
1.0
1.7
|
L
 49.0%
H
0.3
1.7
|
L
 -36.2%
H
0.3
3.8
|
L
 13.2%
H
0.3
9.7
|
L
 -88.5%
H
0.3
19.6
|
| Lyra Therapeutics Inc |
|
6.2
|
3.7
|
L
 -2.9%
H
3.7
4.0
|
L
 -18.9%
H
3.7
4.8
|
L
 -47.7%
H
3.7
7.3
|
L
 -47.0%
H
3.7
8.8
|
L
 -56%
H
3.7
37.5
|
L
 -98.1%
H
3.7
339.5
|
L
 -99.3%
H
3.7
825
|
L
H
3.7
1100
|
| Legend Biotech Corp ADR |
|
5,489.0
|
29.7
|
L
 -1.9%
H
29.7
30.6
|
L
 -6.5%
H
29.7
33.5
|
L
 -8.2%
H
29.7
33.5
|
L
 -20.8%
H
29.7
38.1
|
L
 -22.2%
H
27.3
45.3
|
L
 -42.5%
H
27.3
77.3
|
L
 7.6%
H
23.4
77.3
|
L
H
23.4
77.3
|
| Mustang Bio Inc |
|
8.5
|
1.2
|
L
 -4.9%
H
1.2
1.3
|
L
 -4.9%
H
1.1
1.3
|
L
 -23.7%
H
1.1
1.7
|
L
 -34.5%
H
1.1
1.9
|
L
 -89.8%
H
0.1
21.9
|
L
 -99.7%
H
0.1
554.2
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
20.8
|
0.4
|
L
 -2.3%
H
0.4
0.5
|
L
 -14.3%
H
0.4
0.5
|
L
 -12.5%
H
0.4
0.6
|
L
 -38.2%
H
0.4
0.7
|
L
 -84.5%
H
0.3
3.7
|
L
 -97.3%
H
0.3
132.8
|
L
 -99.4%
H
0.3
132.8
|
L
H
0.3
862.2
|
| Madrigal Pharmaceuticals Inc |
|
12,569.0
|
553.4
|
L
 4.6%
H
520.5
555.1
|
L
 13.1%
H
486.0
555.1
|
L
 25.2%
H
393.6
555.1
|
L
 49.6%
H
351.3
555.1
|
L
 91.8%
H
265
555.1
|
L
 688.3%
H
57.2
555.1
|
L
 357.6%
H
52.3
555.1
|
L
 3599.3%
H
5.3
555.1
|
| MediWound |
|
235.7
|
18.4
|
L
 0.7%
H
18.0
18.9
|
L
 4.7%
H
17.8
18.9
|
L
 -5.6%
H
17.5
20.0
|
L
 1.6%
H
16.1
20.3
|
L
 15.5%
H
14.1
22.5
|
L
 76.2%
H
7.1
24
|
L
 -30.4%
H
7.1
43.5
|
L
 -71.2%
H
7.1
73.3
|
| Lite Strategy Inc |
|
67.7
|
1.9
|
L
 -5.9%
H
1.8
2.1
|
L
 -9.5%
H
1.8
2.3
|
L
 2.7%
H
1.8
2.3
|
L
 -61.2%
H
1.8
5.5
|
L
 -34.9%
H
1.5
9
|
L
 -73.6%
H
1.5
9
|
L
 -96.7%
H
1.5
91.5
|
L
 -94.3%
H
1.5
102.8
|
| Macrogenics Inc |
|
95.5
|
1.5
|
L
 0.7%
H
1.5
1.6
|
L
 10.2%
H
1.4
1.7
|
L
 -10.7%
H
1.3
2.2
|
L
 -4.4%
H
1.3
2.2
|
L
 -57.8%
H
1.0
3.8
|
L
 -77.6%
H
1.0
21.9
|
L
 -92.9%
H
1.0
36.5
|
L
 -95.3%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
14.4
|
1.3
|
L
 -14.9%
H
1.2
1.4
|
L
 -43.0%
H
1.0
2.4
|
L
 -48.8%
H
1.0
2.8
|
L
 -23.2%
H
1.0
2.8
|
L
 -45.5%
H
1.0
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
41.4
|
L
 1.2%
H
40.2
43.7
|
L
 14.0%
H
34.3
43.7
|
L
 14.9%
H
32.2
43.7
|
L
 99.4%
H
20.3
43.7
|
L
 110.0%
H
16.6
43.7
|
L
 62.5%
H
5.1
43.7
|
L
 -62.6%
H
5.1
227.2
|
L
H
5.1
336
|
| Mirum Pharmaceuticals Inc |
|
3,711.1
|
72.2
|
L
 1.1%
H
71.1
73.0
|
L
 6.0%
H
67.4
74.5
|
L
 -3.0%
H
66.8
74.6
|
L
 6.3%
H
64.8
78.5
|
L
 62.3%
H
36.9
78.5
|
L
 268.8%
H
17.5
78.5
|
L
 257.7%
H
12.8
78.5
|
L
H
6.5
78.5
|
| Milestone Pharmaceuticals Inc |
|
197.2
|
2.3
|
L
 16%
H
2.0
2.4
|
L
 35.7%
H
1.7
2.4
|
L
 17.8%
H
1.7
2.4
|
L
 36.5%
H
1.6
2.4
|
L
 36.5%
H
0.6
2.6
|
L
 -48.8%
H
0.6
5.2
|
L
 -64.7%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics |
|
920.3
|
13.0
|
L
 1.7%
H
12.7
13.2
|
L
 22.2%
H
10.5
13.2
|
L
 38.5%
H
8.8
13.2
|
L
 -76.1%
H
6.0
62.8
|
L
 -73.4%
H
6.0
62.8
|
L
 37.9%
H
6.0
65.0
|
L
 24.3%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,529.2
|
5.0
|
L
 -1.6%
H
5.0
5.1
|
L
 -11.6%
H
5.0
5.5
|
L
 -6.9%
H
5.0
6.2
|
L
 33.5%
H
3.7
6.2
|
L
 -26.8%
H
3.4
7.1
|
L
 20%
H
3.2
7.6
|
L
 76.0%
H
2.5
7.6
|
L
 -55.9%
H
0.7
12.7
|
| Mind Medicine Inc |
|
1,102.5
|
11.3
|
L
 -0.1%
H
11.2
11.6
|
L
 -3.1%
H
11.1
13.2
|
L
 -4.8%
H
10.6
14.4
|
L
 18%
H
8.7
14.4
|
L
 46.1%
H
4.7
14.4
|
L
 287.0%
H
2.1
14.4
|
L
 -30.6%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
69.2
|
1.4
|
L
 -9.0%
H
1.4
1.5
|
L
 -0.7%
H
1.4
1.6
|
L
 12.8%
H
1.2
2.0
|
L
 7.6%
H
1.2
2.0
|
L
 -23.0%
H
1.1
2.5
|
L
 -34.4%
H
1.1
2.7
|
L
 -77.1%
H
1.1
10.8
|
L
 -55.0%
H
1.1
14.5
|
| QC Technologies Inc |
|
8.2
|
2.8
|
L
 -6.8%
H
2.5
3
|
L
 -8%
H
2.5
3.7
|
L
 -49.8%
H
2.5
5.5
|
L
 -72.7%
H
2.5
10.3
|
L
 -97.7%
H
2.5
164
|
L
 -100.0%
H
2.5
8940
|
L
 -100.0%
H
2.5
29850
|
L
 -100.0%
H
2.5
29850
|
| NewAmsterdam Pharma Company NV |
|
4,372.3
|
38.6
|
L
 0.6%
H
37.8
39.7
|
L
 4.9%
H
34.5
40.3
|
L
 5.7%
H
34.3
41.0
|
L
 53.8%
H
23.1
41.5
|
L
 54.9%
H
14.1
41.5
|
L
 300.4%
H
5.6
41.5
|
L
H
5.6
41.5
|
L
H
5.6
41.5
|
| Neurocrine Biosciences Inc |
|
14,313.8
|
143.6
|
L
 -0.9%
H
142.4
145.9
|
L
 -5.8%
H
142.4
154.1
|
L
 4.4%
H
133.6
157.7
|
L
 8.0%
H
131.9
157.7
|
L
 22.2%
H
84.2
157.7
|
L
 27.4%
H
84.2
158.0
|
L
 54.4%
H
71.9
158.0
|
L
 176.5%
H
31.3
158.0
|
| Minerva Neurosciences Inc |
|
30.5
|
4.4
|
L
 6.1%
H
3.9
4.6
|
L
 17.5%
H
3.6
4.6
|
L
 72.3%
H
2.4
12.5
|
L
 93.8%
H
1.9
12.5
|
L
 98.2%
H
1.2
12.5
|
L
 32.5%
H
1.2
13.5
|
L
 -84.9%
H
1.2
32.9
|
L
 -89.6%
H
1.2
126.7
|
| Nektar Therapeutics |
|
1,212.0
|
59.6
|
L
 5.1%
H
57.1
60.8
|
L
 6.5%
H
52.5
60.8
|
L
 8.4%
H
52.5
66.9
|
L
 118.6%
H
25.3
66.9
|
L
 271.2%
H
6.5
66.9
|
L
 12.8%
H
6.2
66.9
|
L
 -76.6%
H
6.2
401.3
|
L
 -71.0%
H
6.2
1670.4
|
| NewcelX |
|
15.9
|
3.5
|
L
 -0.3%
H
3.4
3.7
|
L
 -13.2%
H
3.3
4.2
|
L
 -78.7%
H
3.3
17.3
|
L
 -86.1%
H
3.3
28.0
|
L
 -88.9%
H
3.3
37.2
|
L
 -98.3%
H
1.2
752
|
L
H
1.2
2940
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,296.5
|
12.8
|
L
 -0.1%
H
12.6
13.4
|
L
 3.9%
H
12.0
13.4
|
L
 27.5%
H
9.7
13.4
|
L
 20.9%
H
8.2
13.4
|
L
 -47.7%
H
8.2
23
|
L
 -6.8%
H
4.2
29.6
|
L
 -60.1%
H
4.2
52.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics |
|
30.7
|
1.0
|
L
 6.1%
H
1.0
1.1
|
L
 11.8%
H
0.9
1.1
|
L
 -14.8%
H
0.9
1.3
|
L
 -12.6%
H
0.9
2.0
|
L
 -15.5%
H
0.8
2.6
|
L
 -42.2%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharmaceuticals Inc |
|
50.2
|
2.1
|
L
 -15.3%
H
2.1
2.5
|
L
 -13.9%
H
2.1
2.8
|
L
 -30.6%
H
2.1
3.4
|
L
 -27.0%
H
2.1
3.8
|
L
 77.3%
H
1.1
6.0
|
L
 -79.9%
H
1.1
54
|
L
 -98.0%
H
1.1
769.9
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
155.7
|
6.1
|
L
 1%
H
5.9
6.1
|
L
 -1.0%
H
5.9
6.4
|
L
 -0.2%
H
5.6
7
|
L
 -5.4%
H
5.6
7
|
L
 16.5%
H
4.4
11.5
|
L
 -14.4%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
27.2
|
10.1
|
L
 2.6%
H
9.8
10.3
|
L
 13.2%
H
8.1
10.7
|
L
 16.6%
H
7.9
13.2
|
L
 98.1%
H
4.8
13.2
|
L
 -35.5%
H
2.8
16.8
|
L
 -45.8%
H
2.8
30.8
|
L
 -91.6%
H
2.8
172.8
|
L
H
2.8
1308
|
| Ocugen Inc |
|
362.3
|
1.2
|
L
 -2.5%
H
1.1
1.3
|
L
 -14.7%
H
1.1
1.4
|
L
 -28.0%
H
1.1
1.7
|
L
 10.5%
H
1.0
1.9
|
L
 23.4%
H
0.5
1.9
|
L
 -29.7%
H
0.3
2.1
|
L
 314.3%
H
0.3
18.8
|
L
 -99.5%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,107.0
|
19.2
|
L
 -2.3%
H
19.0
19.7
|
L
 -0.4%
H
18.9
19.9
|
L
 -11.1%
H
18.9
22
|
L
 7.0%
H
16
22
|
L
 35.4%
H
14
23.1
|
L
 91.5%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
| Ocular Therapeutix Inc |
|
2,533.1
|
11.9
|
L
 5.2%
H
11.1
12.0
|
L
 9.6%
H
10.7
12.0
|
L
 -2.5%
H
10.3
12.2
|
L
 -5.8%
H
10.3
13.9
|
L
 25.0%
H
5.8
13.9
|
L
 288.6%
H
2
13.9
|
L
 -13.7%
H
2
24.3
|
L
 41.7%
H
2
24.3
|
| Opus Genetics Inc |
|
120.0
|
1.7
|
L
 -7.5%
H
1.7
1.9
|
L
 -13%
H
1.7
2.0
|
L
 -13.4%
H
1.7
2.4
|
L
 45%
H
1.1
2.4
|
L
 64.2%
H
0.7
2.4
|
L
 -36.7%
H
0.7
6.6
|
L
 -66.7%
H
0.7
13.8
|
L
 -99.2%
H
0.7
340.8
|
| Olema Pharmaceuticals Inc |
|
585.0
|
8.5
|
L
 1.4%
H
8.2
8.8
|
L
 2.0%
H
7.8
8.8
|
L
 -11.3%
H
6.7
9.6
|
L
 54.6%
H
5.3
11.5
|
L
 -7.5%
H
2.9
11.5
|
L
 175.7%
H
2.2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
| Omeros Corporation |
|
617.9
|
9.1
|
L
 15.4%
H
7.7
9.1
|
L
 37.8%
H
6.2
9.1
|
L
 -7.6%
H
6.2
9.7
|
L
 105.9%
H
3.9
12.1
|
L
 34.5%
H
3.0
13.6
|
L
 230.2%
H
0.9
13.6
|
L
 -24.0%
H
0.9
23.9
|
L
 -33.8%
H
0.9
27.1
|
| ORIC Pharmaceuticals Inc |
|
1,171.3
|
12.1
|
L
 -1.6%
H
11.3
12.7
|
L
 -2.4%
H
11.3
13.5
|
L
 -9.3%
H
11.3
13.8
|
L
 24.8%
H
9.3
14.9
|
L
 41.9%
H
3.9
14.9
|
L
 218.2%
H
2.9
16.7
|
L
 -51.7%
H
2.4
40.8
|
L
H
2.4
40.8
|
| Oramed Pharmaceuticals Inc |
|
93.2
|
2.3
|
L
 0.4%
H
2.3
2.4
|
L
 6.9%
H
2.2
2.5
|
L
 3.1%
H
2.1
2.5
|
L
 12.5%
H
2.0
2.7
|
L
 4.9%
H
1.8
3.1
|
L
 -71.6%
H
1.7
13.7
|
L
 -10%
H
1.7
31.5
|
L
 -66.6%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
78.6
|
1.8
|
L
 12.7%
H
1.6
2.0
|
L
 48.7%
H
1.2
2.0
|
L
 32.1%
H
1.1
2.0
|
L
 -24.4%
H
0.8
3.0
|
L
 -67.3%
H
0.8
5.5
|
L
 -99.6%
H
0.8
812
|
L
 -99.6%
H
0.8
1704
|
L
H
0.8
17568
|
| Ovid Therapeutics Inc |
|
92.6
|
1.3
|
L
H
1.3
1.4
|
L
 -1.5%
H
1.2
1.4
|
L
 -17.2%
H
1.2
1.7
|
L
 34.0%
H
0.8
2.0
|
L
 22.6%
H
0.2
2.0
|
L
 -21.7%
H
0.2
4.1
|
L
 -78.3%
H
0.2
7.0
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp |
|
1,826.4
|
45.1
|
L
 -0.1%
H
44.2
46.3
|
L
 3.0%
H
43.3
46.4
|
L
 16.8%
H
38.1
46.4
|
L
 46.9%
H
30.5
46.4
|
L
 84.2%
H
16.2
46.4
|
L
 250.9%
H
9.4
46.4
|
L
 138.5%
H
9.4
46.4
|
L
 42.1%
H
9.4
54.6
|
| Palisade Bio Inc |
|
308.9
|
2.1
|
L
 -3.3%
H
2.0
2.3
|
L
 23.2%
H
1.7
2.3
|
L
 19.7%
H
1.5
2.3
|
L
 158.8%
H
0.5
2.3
|
L
 -17.9%
H
0.5
3.3
|
L
 -95.1%
H
0.4
128.1
|
L
 -99.9%
H
0.4
12015
|
L
 -100.0%
H
0.4
1404000
|
| Puma Biotechnology Inc |
|
249.9
|
5.0
|
L
 1.4%
H
4.9
5.1
|
L
 -17.2%
H
4.6
6.1
|
L
 -8.3%
H
4.6
6.1
|
L
 -13.4%
H
4.3
6.1
|
L
 105.0%
H
2.3
6.1
|
L
 58.0%
H
2.1
7.7
|
L
 -45.4%
H
1.6
14.1
|
L
 -92.8%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
1,027.3
|
23.9
|
L
 0.4%
H
23.6
24.9
|
L
 8.3%
H
21.7
24.9
|
L
 4.9%
H
19.8
24.9
|
L
 -3.6%
H
19.8
27.6
|
L
 43.9%
H
16
27.6
|
L
 -50.2%
H
11.2
50.1
|
L
 -62.9%
H
11.2
82.2
|
L
 -57.1%
H
11.2
82.2
|
| Processa Pharmaceuticals Inc |
|
15.3
|
0.3
|
L
 -10%
H
0.3
0.3
|
L
 -12.9%
H
0.3
0.4
|
L
 -25%
H
0.3
0.4
|
L
 22.7%
H
0.2
0.6
|
L
 -73.3%
H
0.2
1.5
|
L
 -87.0%
H
0.2
5.9
|
L
 -94%
H
0.2
14.2
|
L
 -99.0%
H
0.2
35.9
|
| PDS Biotechnology Corporation |
|
42.7
|
0.8
|
L
 -7.1%
H
0.8
0.8
|
L
 -14.3%
H
0.8
1.2
|
L
 -17.9%
H
0.8
1.2
|
L
 -34.5%
H
0.8
1.5
|
L
 -61.2%
H
0.8
2.5
|
L
 -90.8%
H
0.8
13.7
|
L
 -62.3%
H
0.8
17.9
|
L
 -99.7%
H
0.6
355.4
|
| Phathom Pharmaceuticals Inc |
|
1,025.1
|
14.4
|
L
 -1.0%
H
14.2
15.2
|
L
 8.8%
H
13.4
15.3
|
L
 8.3%
H
12.3
16.1
|
L
 40.7%
H
9.8
16.1
|
L
 64.1%
H
2.2
16.1
|
L
 43.4%
H
2.2
19.7
|
L
 -66.3%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
1,618.8
|
24.9
|
L
 5.8%
H
23.0
25.5
|
L
 15.4%
H
21.2
26.1
|
L
 14%
H
20.7
26.1
|
L
 11.8%
H
20.7
26.1
|
L
 22.5%
H
11.5
26.3
|
L
 885.0%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
4,940.9
|
197.6
|
L
 6.0%
H
185.3
198.4
|
L
 17.5%
H
160.4
198.4
|
L
 21.4%
H
154.5
206.7
|
L
 319.7%
H
37.2
206.7
|
L
 175.3%
H
26.7
206.7
|
L
 524.3%
H
11.9
206.7
|
L
 -58.2%
H
11.9
914.3
|
L
H
11.9
914.3
|
| PainReform |
|
1.8
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 -12%
H
0.9
1
|
L
 -29.0%
H
0.9
1.3
|
L
 -34.8%
H
0.9
3.6
|
L
 69.2%
H
0.5
16.6
|
L
 -97.3%
H
0.2
158.5
|
L
 -99.7%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
216.0
|
2.1
|
L
 -5.5%
H
2.0
2.2
|
L
 -7.7%
H
2.0
2.3
|
L
 -26.8%
H
2.0
3.1
|
L
H
1.9
3.1
|
L
 -44.9%
H
1.1
4.0
|
L
 113.5%
H
1.0
4.6
|
L
 -47.0%
H
0.5
9.5
|
L
 -83.9%
H
0.5
24
|
| Plus Therapeutics Inc |
|
66.0
|
0.5
|
L
 -5.9%
H
0.5
0.6
|
L
 -11.1%
H
0.5
0.6
|
L
 -21.3%
H
0.5
0.7
|
L
 -23.8%
H
0.4
0.9
|
L
 -59.0%
H
0.2
2.3
|
L
 -92.7%
H
0.2
7.5
|
L
 -98.6%
H
0.2
81.3
|
L
 -100.0%
H
0.2
46125
|
| PTC Therapeutics Inc |
|
6,069.8
|
75.6
|
L
 0.4%
H
74.7
77.4
|
L
 5.3%
H
70.5
77.4
|
L
 13.1%
H
65.2
77.4
|
L
 54.9%
H
47.9
77.4
|
L
 92.7%
H
36.0
77.4
|
L
 102.2%
H
17.5
77.4
|
L
 23.5%
H
17.5
77.4
|
L
 145.2%
H
4.0
77.4
|
| Protagenic Therapeutics Inc |
|
4.0
|
2.1
|
L
 2.0%
H
2.0
2.1
|
L
 0.5%
H
1.8
2.1
|
L
 -32.1%
H
1.8
3.3
|
L
 -29.4%
H
1.8
6.2
|
L
 233.9%
H
0.2
14.3
|
L
 -4.2%
H
0.2
14.3
|
L
 -50.7%
H
0.2
28
|
L
 -100.0%
H
0.2
2200044.7
|
| Pulmatrix Inc |
|
17.3
|
4.8
|
L
 0.9%
H
4.7
5.0
|
L
 -2.1%
H
4.6
5.0
|
L
 2.4%
H
4.5
5.2
|
L
 0.9%
H
4.3
5.5
|
L
 -27.6%
H
4.3
10.4
|
L
 24.3%
H
1.6
10.4
|
L
 -78.4%
H
1.6
60.8
|
L
 -99.5%
H
1.6
1396
|
| Polypid |
|
57.9
|
3.6
|
L
 1.4%
H
3.6
3.7
|
L
 -0.3%
H
3.5
3.8
|
L
 8.7%
H
3.1
3.9
|
L
 5.5%
H
3.1
3.9
|
L
 2.5%
H
2.3
3.9
|
L
 -84.1%
H
2.3
38.7
|
L
 -98.7%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
289.5
|
4.7
|
L
 6.7%
H
4.3
4.7
|
L
 18.9%
H
4.0
4.8
|
L
 38.8%
H
3.2
4.8
|
L
 278.1%
H
1.1
4.8
|
L
 11.0%
H
0.8
4.8
|
L
 218.5%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Group NV ADR |
|
1,112.0
|
16.2
|
L
 -3.5%
H
16.2
17.1
|
L
 5.2%
H
15.8
17.8
|
L
 12.9%
H
12.7
17.8
|
L
 39.3%
H
12.0
17.8
|
L
 98.4%
H
7.3
17.8
|
L
 38.2%
H
6.7
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
| Purple Biotech ADR |
|
6.5
|
0.7
|
L
H
0.7
0.8
|
L
 -12.2%
H
0.7
0.9
|
L
 16.1%
H
0.6
1.4
|
L
 -68.8%
H
0.5
2.4
|
L
 -72.4%
H
0.5
13.4
|
L
 -98.3%
H
0.5
47.4
|
L
 -99.1%
H
0.5
145
|
L
H
0.5
1390
|
| Qilian International Holding |
|
1,825.7
|
9.1
|
L
 -1.9%
H
9.1
9.3
|
L
 -6.2%
H
9.0
9.7
|
L
 -3.0%
H
8.9
10.1
|
L
 20.2%
H
7
11.8
|
L
 37.7%
H
6.6
17.2
|
L
 51.7%
H
1.8
17.2
|
L
H
1
110
|
L
H
1
110
|
| Quoin Pharmaceuticals ADR |
|
13.6
|
16.2
|
L
 7.9%
H
14.8
17.8
|
L
 79.9%
H
8.1
17.8
|
L
 19.7%
H
8.1
17.8
|
L
 116.7%
H
6.8
41.8
|
L
 -96.2%
H
5.1
966
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| RAPT Therapeutics Inc |
|
793.9
|
28.7
|
L
 -0.7%
H
28.5
29.5
|
L
 -0.7%
H
26.8
30.1
|
L
 -1.0%
H
25.5
42.4
|
L
 144.0%
H
10.1
42.4
|
L
 224.1%
H
5.7
42.4
|
L
 -83.5%
H
5.7
251.6
|
L
 -78.2%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
3,139.4
|
32.5
|
L
 -1.6%
H
32.3
33.4
|
L
 6.2%
H
30.4
34.0
|
L
 -4.2%
H
28.6
36.0
|
L
 9.6%
H
27.8
36.0
|
L
 -27.3%
H
25.8
50
|
L
 -7.6%
H
25.8
60.4
|
L
 -72.6%
H
25.8
179.7
|
L
 -66.2%
H
25.8
179.7
|
| Regeneron Pharma |
|
74,022.6
|
704.3
|
L
 1.6%
H
692.3
711.9
|
L
 7.1%
H
651.4
713.6
|
L
 23.7%
H
566.1
713.6
|
L
 21.5%
H
541
713.6
|
L
 -7.1%
H
476.5
801.0
|
L
 -4.3%
H
476.5
1211.2
|
L
 25.9%
H
441
1211.2
|
L
 26.1%
H
271.4
1211.2
|
| Regencell Bioscience Holdings |
|
6,393.7
|
12.9
|
L
 2.6%
H
12.6
13.1
|
L
 -0.7%
H
12.6
14.9
|
L
 -28.0%
H
12.6
18.1
|
L
 -1.5%
H
12.0
21.8
|
L
 7981.3%
H
0.1
83.6
|
L
 1557.7%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,387.3
|
149
|
L
 -2.2%
H
148.5
154.8
|
L
 4.3%
H
144.4
158.7
|
L
 -3.6%
H
139.4
169.9
|
L
 19.8%
H
112.7
169.9
|
L
 16.9%
H
103.0
182.5
|
L
 -22.0%
H
103.0
211.1
|
L
 -23.7%
H
103.0
327.3
|
L
 469.1%
H
20.1
327.3
|
| Regenxbio Inc |
|
563.9
|
11.1
|
L
 -3.2%
H
11.0
11.8
|
L
 -0.6%
H
10.9
12.1
|
L
 -9.7%
H
10.8
13.9
|
L
 26.3%
H
7.8
13.9
|
L
 15.7%
H
5.0
13.9
|
L
 -47.5%
H
5.0
28.8
|
L
 -68.9%
H
5.0
50.3
|
L
 -47.8%
H
5.0
85.1
|
| Rigel Pharmaceuticals |
|
771.6
|
42.5
|
L
 1.4%
H
40.9
42.7
|
L
 20.8%
H
34
42.7
|
L
 51.2%
H
27.8
42.7
|
L
 7.6%
H
26.4
43.7
|
L
 58.9%
H
14.6
43.7
|
L
 5568%
H
0.7
43.7
|
L
 1451.5%
H
0.6
43.7
|
L
 1317%
H
0.6
43.7
|
| Relmada Therapeutics Inc |
|
291.1
|
4.0
|
L
 0.5%
H
3.9
4.3
|
L
 49.8%
H
2.7
4.3
|
L
 97.5%
H
1.8
4.3
|
L
 510.8%
H
0.6
4.3
|
L
 31.5%
H
0.2
4.3
|
L
 -31.3%
H
0.2
7.2
|
L
 -88.0%
H
0.2
40
|
L
 -66.9%
H
0.2
54
|
| RenovoRx Inc |
|
29.3
|
0.8
|
L
 6.7%
H
0.8
0.9
|
L
 -16.7%
H
0.7
1.1
|
L
 -31.6%
H
0.7
1.2
|
L
 -16.7%
H
0.7
1.5
|
L
 -26.6%
H
0.7
1.7
|
L
 -60%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences |
|
14,299.3
|
20.6
|
L
 1.3%
H
20.1
20.7
|
L
 -0.3%
H
19.8
21.4
|
L
 20.2%
H
16.9
21.4
|
L
 73.5%
H
11.5
21.4
|
L
 83.6%
H
8.7
21.4
|
L
 293.1%
H
4.7
21.4
|
L
H
2.5
21.4
|
L
H
2.5
21.4
|
| Royalty Pharma plc Ordinary |
|
16,731.0
|
39.2
|
L
H
39.0
39.5
|
L
 1.6%
H
38.4
40.0
|
L
 7.8%
H
35.9
41.2
|
L
 7.7%
H
34.1
41.2
|
L
 52.4%
H
24.1
41.2
|
L
 -8.0%
H
24.1
44.5
|
L
 -6.4%
H
24.1
53.2
|
L
H
24.1
56.5
|
| Repare Therapeutics Inc |
|
93.7
|
2.2
|
L
 32.1%
H
2.0
2.2
|
L
 29.0%
H
1.7
2.2
|
L
 17.2%
H
1.7
2.2
|
L
 38.9%
H
1.5
2.2
|
L
 -25.1%
H
0.9
4.1
|
L
 -87.2%
H
0.9
18.7
|
L
 -92.2%
H
0.9
46.4
|
L
H
0.9
46.4
|
| Reviva Pharmaceuticals |
|
54.8
|
0.5
|
L
 -4%
H
0.5
0.5
|
L
 -4%
H
0.5
0.6
|
L
 -18.6%
H
0.4
0.7
|
L
 -11.1%
H
0.3
0.9
|
L
 -56.4%
H
0.3
4.3
|
L
 -88.9%
H
0.3
9.3
|
L
 -95.6%
H
0.3
15.1
|
L
H
0.3
15.1
|
| Rezolute Inc |
|
947.7
|
10.2
|
L
 3.6%
H
9.6
10.3
|
L
 -5.0%
H
9.5
11.5
|
L
 15.2%
H
8.5
11.5
|
L
 57.2%
H
6.2
11.5
|
L
 93.2%
H
2.2
11.5
|
L
 487.4%
H
0.7
11.5
|
L
 -48.2%
H
0.7
21
|
L
 -87.5%
H
0.7
100
|
| Redhill Biopharma ADR |
|
3.5
|
1.0
|
L
 -2.8%
H
1.0
1.1
|
L
 -8.8%
H
1.0
1.1
|
L
 -33.8%
H
1.0
2.1
|
L
 -23.5%
H
1.0
2.8
|
L
 -85.1%
H
1.0
8.8
|
L
 -99.8%
H
1.0
550
|
L
 -100.0%
H
1.0
11520
|
L
 -100.0%
H
1.0
16540
|
| Sunshine Biopharma Inc |
|
7.5
|
1.5
|
L
 -6.1%
H
1.5
1.7
|
L
 -11.1%
H
1.5
1.8
|
L
 -30.5%
H
1.5
2.2
|
L
 2.7%
H
1.4
2.4
|
L
 -34.6%
H
1.2
3.9
|
L
 -98.2%
H
0.1
140
|
L
 -99.4%
H
0.1
6280
|
L
 -100.0%
H
0.1
300000
|
| Scilex Holding Company |
|
117.7
|
15.5
|
L
 -12.3%
H
15.3
17.5
|
L
 -17.5%
H
15.3
19.6
|
L
 16.6%
H
12.6
21
|
L
 -14.2%
H
12.6
34.3
|
L
 2442.6%
H
0.2
34.3
|
L
 78.1%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
24.3
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 -3.3%
H
0.6
0.6
|
L
 -27.5%
H
0.6
0.8
|
L
 -31.0%
H
0.6
1.3
|
L
 -51.7%
H
0.6
1.5
|
L
 -71.3%
H
0.6
3.9
|
L
 -90.1%
H
0.6
10.3
|
L
 -99.2%
H
0.6
71.8
|
| Shuttle Pharmaceuticals |
|
2.1
|
1.9
|
L
 -17.2%
H
1.9
2.3
|
L
 -23.2%
H
1.9
2.6
|
L
 -47.8%
H
1.9
3.8
|
L
 -42.2%
H
1.9
5.6
|
L
 -92.3%
H
1.9
25.3
|
L
 -99.5%
H
1.9
684
|
L
H
1.9
25252
|
L
H
1.9
25252
|
| SIGA Technologies Inc |
|
422.5
|
5.9
|
L
 -1.7%
H
5.9
6.1
|
L
 -9.8%
H
5.9
6.6
|
L
 -29.3%
H
5.9
8.5
|
L
 -30.6%
H
5.9
9.5
|
L
 -0.7%
H
5.0
9.6
|
L
 -36.8%
H
4.2
12.8
|
L
 -23.6%
H
4.2
27.0
|
L
 917.2%
H
0.2
27.0
|
| SILO Pharma Inc |
|
5.5
|
0.4
|
L
H
0.4
0.5
|
L
 -10.9%
H
0.4
0.5
|
L
 -31.7%
H
0.4
0.6
|
L
 -42.3%
H
0.4
1.0
|
L
 -63.7%
H
0.4
3.4
|
L
 -87.8%
H
0.4
6.6
|
L
 -97.7%
H
0.4
496
|
L
 -99.5%
H
0.4
496
|
| SolGel Technologies |
|
100.3
|
36
|
L
 5.9%
H
34.3
36.4
|
L
 17.5%
H
28.8
38.4
|
L
 -11.1%
H
28.8
43.5
|
L
 133.2%
H
15.0
52.3
|
L
 6823.1%
H
0.4
52.3
|
L
 634.7%
H
0.3
52.3
|
L
 335.8%
H
0.3
52.3
|
L
H
0.3
52.3
|
| Soleno Therapeutics Inc |
|
2,537.8
|
47.3
|
L
 -4.4%
H
47.1
49.5
|
L
 -0.9%
H
45.8
50.8
|
L
 -30.5%
H
41.8
72.8
|
L
 -34.0%
H
41.8
73.0
|
L
 -8.8%
H
41.5
90.3
|
L
 3741.5%
H
0.9
90.3
|
L
 53.7%
H
0.9
90.3
|
L
 -64.8%
H
0.9
194.3
|
| SELLAS Life Sciences Group Inc |
|
200.8
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -11.3%
H
1.4
1.6
|
L
 -34.7%
H
1.4
2.5
|
L
 -13.5%
H
1.4
2.5
|
L
 6.8%
H
0.8
2.5
|
L
 -42.4%
H
0.5
4.1
|
L
 -46.6%
H
0.5
19.4
|
L
 -100.0%
H
0.5
74703
|
| Soligenix Inc |
|
13.6
|
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -12.9%
H
1.3
1.8
|
L
 -51.4%
H
1.1
6.2
|
L
 -62.3%
H
1.1
6.2
|
L
 -99.1%
H
1.1
165.6
|
L
 -99.7%
H
1.1
672.0
|
L
 -99.9%
H
1.1
3455.9
|
| Sonoma Pharmaceuticals Inc |
|
6.2
|
3.6
|
L
 5.2%
H
3.5
3.7
|
L
 -1.6%
H
3.4
3.8
|
L
 -11.3%
H
3.4
4.1
|
L
 -32.3%
H
3.4
5.6
|
L
 41.4%
H
1.8
6.9
|
L
 69.2%
H
0.1
6.9
|
L
 -54.2%
H
0.1
15.2
|
L
 -92.9%
H
0.1
74.2
|
| Synaptogenix Inc |
|
31.5
|
6.4
|
L
 -3.2%
H
5.9
6.7
|
L
 -23.2%
H
5.9
8.8
|
L
 -17.4%
H
5.9
9.4
|
L
 -23.9%
H
5.3
10
|
L
 165.2%
H
1.8
12.0
|
L
 4.6%
H
0.1
12.0
|
L
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc |
|
4.0
|
2.5
|
L
 2.9%
H
2.4
2.6
|
L
 -10.2%
H
2.4
2.8
|
L
 -37.2%
H
2.4
4.5
|
L
 -45.2%
H
1.8
8.9
|
L
 -48.2%
H
1.8
37.6
|
L
 -99.6%
H
1.8
726.2
|
L
H
1.8
4641
|
L
H
1.8
4641
|
| ARS Pharmaceuticals Inc |
|
723.6
|
7.3
|
L
 -10.8%
H
7.3
8.2
|
L
 -17.3%
H
7.3
10.3
|
L
 -27.6%
H
7.3
10.4
|
L
 -49.6%
H
7.3
15.1
|
L
 -47.8%
H
7.3
18.9
|
L
 21.2%
H
2.6
18.9
|
L
H
2.6
63.4
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
125.4
|
2.5
|
L
 0.4%
H
2.5
2.7
|
L
 1.6%
H
2.5
3.0
|
L
 -16.9%
H
2.5
3.1
|
L
 -50.5%
H
2.5
5.2
|
L
 -3.9%
H
1.5
5.3
|
L
 443.5%
H
0.2
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,838.0
|
17.5
|
L
 -6.8%
H
17.4
18.7
|
L
 -0.5%
H
16.9
20.2
|
L
 -24.9%
H
15.1
24.6
|
L
 -19.6%
H
15.1
25.3
|
L
 -83.2%
H
10.4
138.8
|
L
 -83.9%
H
10.4
173.3
|
L
 -87.4%
H
10.4
181.8
|
L
 -32.4%
H
8
181.8
|
| Sutro Biopharma Inc |
|
72.4
|
0.9
|
L
 -5.6%
H
0.9
1.0
|
L
 3.7%
H
0.8
1
|
L
 -3.4%
H
0.8
1.3
|
L
 -3.4%
H
0.8
1.3
|
L
 -70.6%
H
0.5
3.0
|
L
 -88.7%
H
0.5
8.7
|
L
 -95.1%
H
0.5
28.3
|
L
H
0.5
28.3
|
| Supernus Pharmaceuticals Inc |
|
2,585.4
|
45.1
|
L
 0.2%
H
44.7
46.0
|
L
 -2.0%
H
44.1
46.6
|
L
 -9.4%
H
43.1
57.7
|
L
 5.6%
H
41.8
57.7
|
L
 26.8%
H
29.2
57.7
|
L
 33.7%
H
22
57.7
|
L
 101.7%
H
20.3
57.7
|
L
 179.9%
H
9.5
61.3
|
| Savara Inc |
|
854.6
|
4.2
|
L
 -2.3%
H
4.2
4.4
|
L
 6.3%
H
3.9
4.4
|
L
 17.3%
H
3.5
4.5
|
L
 38.2%
H
2.9
4.5
|
L
 40.9%
H
1.9
4.5
|
L
 218.2%
H
1.2
5.7
|
L
 320%
H
1.0
5.7
|
L
 -85%
H
0.7
49.6
|
| China SXT Pharmaceuticals Inc |
|
156.6
|
1.4
|
L
 2.3%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -4.9%
H
1.2
1.8
|
L
 -15.6%
H
1.1
2.1
|
L
 246.2%
H
0.3
5.7
|
L
 -91.8%
H
0.3
24.5
|
L
 -95.1%
H
0.3
128
|
L
H
0.3
2335
|
| Sanofi ADR |
|
126,134.9
|
51.8
|
L
 -0.7%
H
51.7
52.7
|
L
 4.3%
H
50.0
52.7
|
L
 3.5%
H
48.5
52.7
|
L
 4.0%
H
44.6
52.7
|
L
 7.9%
H
44.6
60.1
|
L
 18.1%
H
42.6
60.1
|
L
 2.2%
H
36.9
60.1
|
L
 20.1%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
214.9
|
5.6
|
L
 1.1%
H
5.4
5.8
|
L
 29.8%
H
4.2
5.8
|
L
 -3.6%
H
4.1
5.8
|
L
 83.8%
H
3.0
5.9
|
L
 125.5%
H
2.2
10.5
|
L
 83.2%
H
1.0
10.5
|
L
 -75.4%
H
1.0
27.5
|
L
 -99.1%
H
1.0
659.2
|
| Tarsus Pharmaceuticals Inc |
|
3,148.5
|
74.2
|
L
 1.7%
H
72.8
76.1
|
L
 8.7%
H
68.4
76.4
|
L
 -1.1%
H
65.3
76.4
|
L
 36.8%
H
48.2
76.8
|
L
 68.6%
H
38.5
76.8
|
L
 339.4%
H
11.3
76.8
|
L
 196.9%
H
10.8
76.8
|
L
H
10.8
76.8
|
| Theravance Biopharma Inc |
|
914.1
|
18.0
|
L
 3.7%
H
17.3
18.4
|
L
 22.3%
H
14.7
19.0
|
L
 28.5%
H
13.7
19.0
|
L
 37.2%
H
13.2
19.0
|
L
 94.4%
H
7.9
19.0
|
L
 60.8%
H
7.4
19.0
|
L
 0.3%
H
6.1
22.7
|
L
 6.9%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
33.5
|
7.4
|
L
 3.5%
H
7.2
7.5
|
L
 4.6%
H
6.6
7.5
|
L
 7.8%
H
6.1
7.8
|
L
 23.1%
H
5.8
8.2
|
L
 48.8%
H
4.6
8.2
|
L
 -96.2%
H
2.8
344
|
L
 -99.6%
H
2.8
5888
|
L
 -100.0%
H
2.8
108800
|
| TG Therapeutics Inc |
|
4,872.3
|
30.7
|
L
 -1%
H
30.3
31.4
|
L
 -4.8%
H
29.8
32.4
|
L
 -12.0%
H
29.8
36.7
|
L
 9.3%
H
27.2
37.6
|
L
 3.9%
H
25.3
46.5
|
L
 262.8%
H
6.5
46.5
|
L
 4.0%
H
3.5
56.7
|
L
 135.9%
H
3.3
56.7
|
| Alpha Teknova Inc |
|
229.1
|
4.3
|
L
 -3.8%
H
4.3
4.6
|
L
 -9.1%
H
4.3
5
|
L
 -18.6%
H
4.3
5.9
|
L
 -8.7%
H
3.9
6.7
|
L
 -27.6%
H
3.9
10.4
|
L
 -21.6%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences |
|
200.8
|
1.7
|
L
 -1.7%
H
1.7
1.8
|
L
 -3.4%
H
1.6
1.8
|
L
 -16.3%
H
1.6
2.1
|
L
 -14.2%
H
1.5
2.4
|
L
 89.9%
H
0.6
2.6
|
L
 148.5%
H
0.4
2.6
|
L
 -43.3%
H
0.4
5.3
|
L
H
0.4
12.2
|
| Tonix Pharmaceuticals Holding |
|
197.8
|
16.8
|
L
 5.7%
H
16.3
18.3
|
L
 -1.2%
H
15.5
18.3
|
L
 -10.7%
H
15.5
20.6
|
L
 -67.3%
H
15.5
53.5
|
L
 28.2%
H
0.2
130
|
L
 -99.8%
H
0.2
31400
|
L
 -100.0%
H
0.2
1356800
|
L
 -100.0%
H
0.2
5090624000
|
| Tenaya Therapeutics Inc |
|
209.8
|
1.3
|
L
 -5.3%
H
1.2
1.4
|
L
 -1.6%
H
1.2
1.6
|
L
 -32.3%
H
1.2
2.0
|
L
 8.6%
H
0.9
2.4
|
L
 -36.0%
H
0.4
4.0
|
L
 -60.5%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
41.6
|
9.4
|
L
 3.4%
H
9.1
9.8
|
L
 -1.5%
H
8.4
10.3
|
L
 -15.4%
H
8.4
11.2
|
L
 -10.9%
H
8.4
12.2
|
L
 953.9%
H
0.4
12.2
|
L
 461.7%
H
0.2
12.2
|
L
 -59.4%
H
0.2
41.6
|
L
 -99.6%
H
0.2
2623.5
|
| Travere Therapeutics Inc |
|
3,170.9
|
35.4
|
L
 2.7%
H
34.3
35.8
|
L
 9.6%
H
32.3
36.8
|
L
 28.8%
H
26.8
36.8
|
L
 88.3%
H
17.1
36.8
|
L
 102.9%
H
12.9
36.8
|
L
 67.5%
H
5.1
36.8
|
L
 47.0%
H
5.1
36.8
|
L
 92.9%
H
5.1
36.8
|
| TherapeuticsMD Inc |
|
17.6
|
1.5
|
L
 -22.5%
H
1.5
2.1
|
L
 9.4%
H
1.3
2.1
|
L
 46.2%
H
1.1
2.1
|
L
 29.9%
H
1.0
2.1
|
L
 8.6%
H
0.7
2.4
|
L
 -72.2%
H
0.7
7.2
|
L
 -97.5%
H
0.7
137.5
|
L
 -99.6%
H
0.7
563
|
| Universe Pharmaceuticals INC |
|
2.1
|
3.7
|
L
H
3.5
3.8
|
L
 -3.2%
H
3.5
3.8
|
L
 -33.0%
H
3.5
5.7
|
L
 3.7%
H
3.3
11
|
L
 73.0%
H
0.1
11
|
L
 -81.8%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
20,319.3
|
471.9
|
L
 1.2%
H
463.9
476.7
|
L
 5.1%
H
445.8
476.7
|
L
 9.1%
H
409.1
479.5
|
L
 50.7%
H
302.2
479.5
|
L
 29.9%
H
267.0
479.5
|
L
 80.8%
H
204.4
479.5
|
L
 230.2%
H
129.4
479.5
|
L
 223.3%
H
74.3
479.5
|
| Vericel Corp |
|
1,994.1
|
39.4
|
L
 -1.1%
H
39.2
40.4
|
L
 1.3%
H
38.0
41.7
|
L
 13.5%
H
33.8
43
|
L
 8.7%
H
29.2
43
|
L
 -25.1%
H
29.2
63
|
L
 75.9%
H
20.4
63
|
L
 53.6%
H
17.3
68.9
|
L
 2127.7%
H
1.7
68.9
|
| Veru Inc |
|
40.8
|
2.5
|
L
H
2.5
2.6
|
L
 -0.8%
H
2.5
2.9
|
L
 -39.1%
H
2.4
4.5
|
L
 -29.3%
H
2.4
4.6
|
L
 -56.5%
H
2.4
14.2
|
L
 -95.8%
H
2.4
66.3
|
L
 -90.7%
H
2.4
245.7
|
L
 -82.7%
H
2.4
245.7
|
| Dogwood Therapeutics Inc |
|
13.0
|
5.7
|
L
 1.8%
H
5.6
6
|
L
 7.8%
H
5.1
6
|
L
 -5.7%
H
5.0
6.9
|
L
 15.0%
H
4.6
9.5
|
L
 90.9%
H
1.6
29.3
|
L
 1729.0%
H
0.1
29.3
|
L
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
4,320.2
|
38.2
|
L
 -2.3%
H
36.9
38.8
|
L
 3.9%
H
36.5
43.2
|
L
 10.1%
H
30.9
43.2
|
L
 -4.5%
H
23.0
43.2
|
L
 -22.9%
H
18.9
56.3
|
L
 818.8%
H
3.5
99.4
|
L
 514.5%
H
2.0
99.4
|
L
 664.4%
H
0.9
99.4
|
| Vanda Pharmaceuticals Inc |
|
260.0
|
4.4
|
L
 1.2%
H
4.3
4.5
|
L
H
4.3
4.5
|
L
 -16.5%
H
4.3
5.7
|
L
 0.9%
H
4.3
5.7
|
L
 -12%
H
3.8
5.7
|
L
 -57.8%
H
3.3
11.0
|
L
 -66.6%
H
3.3
21.9
|
L
 -52.7%
H
3.3
33.4
|
| Verrica Pharmaceuticals Inc |
|
35.2
|
3.7
|
L
 -5.1%
H
3.7
4.0
|
L
 7.8%
H
3.6
4.0
|
L
 -11.8%
H
3.3
4.5
|
L
 -37.4%
H
3.3
6.5
|
L
 349.4%
H
0.4
7.4
|
L
 58.1%
H
0.4
11.4
|
L
 -56.3%
H
0.4
18.4
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
2,765.7
|
29
|
L
 0.8%
H
28.6
29.6
|
L
 5.7%
H
27.2
29.6
|
L
 26.0%
H
21.6
29.6
|
L
 56.4%
H
17.0
29.6
|
L
 45.7%
H
9.9
29.6
|
L
 26.1%
H
9.9
39
|
L
 84.0%
H
9.5
39
|
L
 -83.0%
H
4.7
270
|
| Vertex Pharma |
|
110,119.0
|
434.0
|
L
 -0.7%
H
432.2
440.0
|
L
 6%
H
410.5
442.2
|
L
 6.2%
H
403.2
442.2
|
L
 10.5%
H
374.2
442.2
|
L
 -6.8%
H
362.5
519.7
|
L
 42.1%
H
282.2
519.9
|
L
 93.5%
H
176.4
519.9
|
L
 246.4%
H
71.5
519.9
|
| Viatris |
|
12,277.9
|
10.7
|
L
 -0.6%
H
10.6
10.9
|
L
 5.3%
H
10.0
11.3
|
L
 5.5%
H
9.9
11.3
|
L
 0.5%
H
9.4
11.3
|
L
 -15.0%
H
6.9
13.6
|
L
 -3.8%
H
6.9
13.6
|
L
 -32.8%
H
6.9
18.9
|
L
 -78.7%
H
6.9
55.5
|
| vTv Therapeutics Inc |
|
118.7
|
30.2
|
L
 -2.1%
H
29.4
30.7
|
L
 15.9%
H
25.8
33.1
|
L
 45.0%
H
19.5
33.1
|
L
 95.3%
H
14.6
33.1
|
L
 73.3%
H
13.2
33.1
|
L
 3405.8%
H
0.4
33.1
|
L
 1503.7%
H
0.4
33.1
|
L
 350.7%
H
0.4
33.1
|
| VYNE Therapeutics Inc |
|
12.2
|
0.4
|
L
H
0.4
0.4
|
L
 5.7%
H
0.4
0.4
|
L
 2.8%
H
0.3
0.4
|
L
 5.7%
H
0.3
0.5
|
L
 -86.7%
H
0.3
4.3
|
L
 -91.0%
H
0.3
8.7
|
L
 -99.7%
H
0.3
237.6
|
L
H
0.3
2869.9
|
| Vaccitech plc ADR |
|
29.7
|
0.8
|
L
 -3.8%
H
0.8
0.8
|
L
 -28.0%
H
0.7
1.1
|
L
 -43.0%
H
0.7
1.5
|
L
 -37.9%
H
0.7
1.8
|
L
 -18.1%
H
0.7
2.9
|
L
 -68.0%
H
0.7
5.1
|
L
H
0.7
18.0
|
L
H
0.7
18.0
|
| Xenetic Biosciences Inc |
|
5.7
|
2.5
|
L
 -4.2%
H
2.5
2.7
|
L
 -3.5%
H
2.5
2.8
|
L
 -43.3%
H
2.5
4.5
|
L
 -12.9%
H
2.5
13.9
|
L
 -32.5%
H
2.2
13.9
|
L
 -43.4%
H
2.2
13.9
|
L
 -70.7%
H
2.2
58.5
|
L
 -99.9%
H
2.2
2969.6
|
| Xenon Pharmaceuticals Inc |
|
3,138.1
|
40.6
|
L
 -0.4%
H
40.3
41.6
|
L
 6.2%
H
37.7
41.6
|
L
 -3.7%
H
37.2
44.2
|
L
 6.2%
H
35.6
44.2
|
L
 1.6%
H
26.7
44.2
|
L
 22.8%
H
26.7
51.0
|
L
 272.6%
H
10.0
51.0
|
L
 407.6%
H
2.1
51.0
|
| Xilio Therapeutics Inc |
|
37.3
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 -11.1%
H
0.7
0.8
|
L
 -5.3%
H
0.7
0.9
|
L
 1.4%
H
0.6
0.9
|
L
 -30.8%
H
0.6
1.7
|
L
 -72.5%
H
0.5
4.9
|
L
H
0.5
28.0
|
L
H
0.5
28.0
|
| XOMA Corp |
|
396.6
|
32.0
|
L
 -1.9%
H
31.9
33.1
|
L
 -3.5%
H
31.7
34.9
|
L
 -12.2%
H
31.7
36.6
|
L
 2.1%
H
30.6
39.9
|
L
 6.0%
H
18.4
39.9
|
L
 77.5%
H
13.5
39.9
|
L
 1.1%
H
13.5
46.3
|
L
 20.4%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
3.1
|
0.5
|
L
 -3.6%
H
0.5
0.6
|
L
 -3.6%
H
0.5
0.6
|
L
 -36.5%
H
0.5
1.4
|
L
 -34.2%
H
0.5
1.4
|
L
 -58.1%
H
0.5
1.8
|
L
 -34.1%
H
0.3
7
|
L
 -71.1%
H
0.3
8.2
|
L
H
0.3
8.2
|
| Zevra Therapeutics Inc |
|
516.8
|
9.2
|
L
 3.4%
H
8.9
9.4
|
L
 4.2%
H
8.5
9.7
|
L
 -19.3%
H
8.5
11.5
|
L
 -2.7%
H
7.2
12.0
|
L
 6.5%
H
6.2
13.2
|
L
 109.1%
H
3.9
13.2
|
L
 -5.5%
H
3.9
22.1
|
L
 -96.0%
H
1.9
329.6
|
| Zymeworks BC Inc |
|
1,801.8
|
23.9
|
L
 29.1%
H
22.6
26.2
|
L
 45.2%
H
16.6
26.2
|
L
 28.8%
H
16
26.2
|
L
 66.4%
H
13.5
26.2
|
L
 55.3%
H
9.0
26.2
|
L
 205.6%
H
5.8
26.2
|
L
 -42.6%
H
4.1
59.0
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc |
|
254.0
|
7.8
|
L
 0.8%
H
7.3
8.0
|
L
 3.9%
H
7.3
8.8
|
L
 3.4%
H
7.0
9.5
|
L
 1.8%
H
6.1
9.5
|
L
 65.1%
H
1.7
11.4
|
L
 2.5%
H
1.7
20.7
|
L
 2.5%
H
1.7
20.7
|
L
 2.5%
H
1.7
20.7
|
| CervoMed Inc |
|
76.0
|
8.2
|
L
 6.9%
H
7.9
8.6
|
L
 18.6%
H
6.6
8.6
|
L
 8.0%
H
6.6
8.6
|
L
 -18.9%
H
6.6
11.3
|
L
 -23.8%
H
1.8
16.9
|
L
 -11.4%
H
1.8
26.4
|
L
 -83.4%
H
1.8
138.8
|
L
 -99.9%
H
1.8
29250
|
| Dianthus Therapeutics Inc |
|
1,772.9
|
41.4
|
L
 1.2%
H
40.2
43.7
|
L
 14.0%
H
34.3
43.7
|
L
 14.9%
H
32.2
43.7
|
L
 99.4%
H
20.3
43.7
|
L
 77.0%
H
13.4
43.7
|
L
 5340.8%
H
6.6
43.7
|
L
 5340.8%
H
6.6
43.7
|
L
 5340.8%
H
6.6
43.7
|
| Neumora Therapeutics Inc |
|
432.8
|
2.6
|
L
 -2.3%
H
2.6
2.8
|
L
 1.2%
H
2.6
3
|
L
 45.5%
H
1.7
3.3
|
L
 58.9%
H
1.4
3.3
|
L
 -76.1%
H
0.6
11.6
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
65.0
|
1.3
|
L
 -3.0%
H
1.3
1.4
|
L
 4.8%
H
1.2
1.5
|
L
 4.8%
H
1.2
1.5
|
L
 3.2%
H
1.1
1.5
|
L
 -10.3%
H
0.9
2.9
|
L
 -15.6%
H
0.1
3.5
|
L
 -15.6%
H
0.1
3.5
|
L
 -15.6%
H
0.1
3.5
|
| Barinthus Biotherapeutics Plc |
|
31.4
|
0.8
|
L
 -3.8%
H
0.8
0.8
|
L
 -28.0%
H
0.7
1.1
|
L
 -43.0%
H
0.7
1.5
|
L
 -37.9%
H
0.7
1.8
|
L
 -20.6%
H
0.6
2.9
|
L
 -78.8%
H
0.6
5.1
|
L
 -78.8%
H
0.6
5.1
|
L
 -78.8%
H
0.6
5.1
|
| Onconetix Inc |
|
3.6
|
2.3
|
L
 0.9%
H
2.2
2.3
|
L
 -15.7%
H
2.2
2.9
|
L
 -33.4%
H
2.2
4
|
L
 -21.2%
H
2.2
4.2
|
L
 81.9%
H
0.1
5.9
|
L
 -95.3%
H
0.1
78
|
L
 26.9%
H
0.1
3636
|
L
 26.9%
H
0.1
3636
|
| Talphera Inc |
|
61.5
|
1.3
|
L
 5.6%
H
1.3
1.4
|
L
 6.5%
H
1.0
1.4
|
L
 13.8%
H
1.0
1.4
|
L
 214.3%
H
0.4
1.5
|
L
 91.3%
H
0.4
1.5
|
L
H
0.4
1.5
|
L
H
0.4
1.5
|
L
H
0.4
1.5
|
| ArriVent BioPharma Inc |
|
854.1
|
20.7
|
L
H
20.0
21.1
|
L
 14.7%
H
17.8
21.1
|
L
 5.5%
H
17
21.1
|
L
 5.9%
H
17
21.9
|
L
 -24.1%
H
15.5
30.4
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
44.9
|
1.4
|
L
 7.7%
H
1.4
1.5
|
L
 -8.5%
H
1.3
1.6
|
L
 -3.5%
H
1.3
1.7
|
L
 -60.1%
H
1.3
5.0
|
L
 -71.7%
H
1.1
5.8
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
| Actuate Therapeutics Inc |
|
137.6
|
5.9
|
L
 0.2%
H
5.8
6.2
|
L
 -3.6%
H
5.7
6.4
|
L
 -24.1%
H
5.7
8.0
|
L
 -27.1%
H
5.7
9.2
|
L
 -31.8%
H
5.5
12.0
|
L
H
5.5
12.0
|
L
H
5.5
12.0
|
L
H
5.5
12.0
|
| Bicara Therapeutics Inc |
|
824.5
|
15.1
|
L
 1.8%
H
14.6
15.4
|
L
 2.8%
H
13.7
15.4
|
L
 -19.4%
H
13.7
18.7
|
L
 29.3%
H
10.3
19.7
|
L
 -25.4%
H
7.8
22.7
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq |
|
9.4
|
0.9
|
L
 -6%
H
0.9
1.1
|
L
 -7.8%
H
0.9
1.1
|
L
 -26.6%
H
0.9
1.5
|
L
 -29.3%
H
0.8
2.0
|
L
 -43.0%
H
0.8
5.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
| Septerna Inc |
|
968.9
|
21.6
|
L
 -7.0%
H
21.6
23.2
|
L
 16.9%
H
18.0
24.0
|
L
 -4.1%
H
17.6
24.0
|
L
 84.6%
H
10.7
24.9
|
L
 -4.0%
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
| Alpha Cognition Inc |
|
123.3
|
5.9
|
L
 -0.7%
H
5.8
6.4
|
L
 3.2%
H
5.5
6.5
|
L
 -16.4%
H
5.2
7.3
|
L
 -26.3%
H
5.2
10
|
L
 9.9%
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic International Corp |
|
138.7
|
2.5
|
L
 0.4%
H
2.5
2.7
|
L
 1.6%
H
2.5
3.0
|
L
 -16.9%
H
2.5
3.1
|
L
 -50.5%
H
2.5
5.2
|
L
 -3.9%
H
1.5
5.3
|
L
 -3.8%
H
1.5
5.3
|
L
 -3.8%
H
1.5
5.3
|
L
 -3.8%
H
1.5
5.3
|
| BeiGene ADR |
|
41,677.1
|
376.6
|
L
 3.0%
H
373.3
385.2
|
L
 17.7%
H
327.0
385.2
|
L
 18.4%
H
306
385.2
|
L
 17.2%
H
295.2
385.2
|
L
 103.9%
H
172.7
385.2
|
L
 103.9%
H
172.7
385.2
|
L
 103.9%
H
172.7
385.2
|
L
 103.9%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
43.7
|
1.3
|
L
 -5.2%
H
1.3
1.4
|
L
 -4.5%
H
1.3
1.4
|
L
 -22.1%
H
1.2
1.8
|
L
 -1.6%
H
1.2
1.8
|
L
 119.0%
H
0.6
3.3
|
L
 119.0%
H
0.6
3.3
|
L
 119.0%
H
0.6
3.3
|
L
 119.0%
H
0.6
3.3
|
| Ascentage Pharma Group |
|
3,040.8
|
32.7
|
L
 -4.6%
H
32.7
32.7
|
L
 3.1%
H
30.9
34.5
|
L
 -10.3%
H
30.9
35.9
|
L
 -27.3%
H
30.9
48.5
|
L
 88.2%
H
17
48.5
|
L
 88.2%
H
17
48.5
|
L
 88.2%
H
17
48.5
|
L
 88.2%
H
17
48.5
|
| Maze Therapeutics Inc |
|
1,613.4
|
33.5
|
L
 3.1%
H
32.4
34.7
|
L
 17.2%
H
28.2
34.7
|
L
 17.9%
H
27.0
34.7
|
L
 148.4%
H
12.8
34.7
|
L
H
6.7
34.7
|
L
H
6.7
34.7
|
L
H
6.7
34.7
|
L
H
6.7
34.7
|
| Aardvark Therapeutics Inc |
|
224.7
|
10.4
|
L
 4.4%
H
9.9
10.9
|
L
 2.2%
H
9.8
11.5
|
L
 -22.1%
H
9.3
13.4
|
L
 -3.9%
H
7.5
17.9
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
| Cuprina Holdings Cayman |
|
5.5
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 -10.8%
H
0.7
0.8
|
L
 -20.4%
H
0.7
1.2
|
L
 -37.8%
H
0.6
2.5
|
L
H
0.6
9.5
|
L
H
0.6
9.5
|
L
H
0.6
9.5
|
L
H
0.6
9.5
|
| Jyong Biotech |
|
2,335.6
|
30.7
|
L
 -19.6%
H
29
40.3
|
L
 -21.0%
H
29
41.2
|
L
 -47.5%
H
29
63
|
L
 -31.3%
H
29
67
|
L
 203.9%
H
6.0
67
|
L
 203.9%
H
6.0
67
|
L
 203.9%
H
6.0
67
|
L
 203.9%
H
6.0
67
|
| Black Titan Corp |
|
22.1
|
3.1
|
L
 -7.3%
H
3.0
3.3
|
L
 -6.1%
H
3.0
3.7
|
L
 -37.4%
H
3.0
5.9
|
L
 -87.2%
H
3.0
23.5
|
L
 -87.2%
H
3.0
23.5
|
L
 -87.2%
H
3.0
23.5
|
L
 -87.2%
H
3.0
23.5
|
L
 -87.2%
H
3.0
23.5
|
| MapLight Therapeutics Inc |
|
567.2
|
13.7
|
L
 -2.8%
H
13.7
14.6
|
L
 -12.3%
H
13.3
16.2
|
L
 -25.4%
H
13.3
19.4
|
L
 -25.4%
H
13.3
19.4
|
L
 -25.4%
H
13.3
19.4
|
L
 -25.4%
H
13.3
19.4
|
L
 -25.4%
H
13.3
19.4
|
L
 -25.4%
H
13.3
19.4
|
| NovaBridge Biosciences ADR |
|
-
|
4.4
|
L
 5.3%
H
4.0
4.4
|
L
 9.3%
H
4.0
4.4
|
L
 -4.0%
H
3.8
5.1
|
L
 -4.0%
H
3.8
5.1
|
L
 -4.0%
H
3.8
5.1
|
L
 -4.0%
H
3.8
5.1
|
L
 -4.0%
H
3.8
5.1
|
L
 -4.0%
H
3.8
5.1
|
| Evommune Inc |
|
585.0
|
19.5
|
L
 6.3%
H
18.2
20
|
L
 5.7%
H
17.0
20.4
|
L
 -3.9%
H
17.0
24.0
|
L
 -3.9%
H
17.0
24.0
|
L
 -3.9%
H
17.0
24.0
|
L
 -3.9%
H
17.0
24.0
|
L
 -3.9%
H
17.0
24.0
|
L
 -3.9%
H
17.0
24.0
|